Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
  • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
  • C07K2317/522—CH1 domain
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
  • C07K2317/524—CH2 domain
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

• Methods of treating a hematological malignancy, particularly relapsed or refractory multiple myeloma, using a GPRC5DxCD3 bispecific antibody are disclosed.
• G-protein coupled receptor, class C, group 5, member D is an orphan, atypical, class C GPCR first identified in 2001 (Brauner-Osbome et al., Biochim Biophys Acta., 1518(3):237-248, 2001).
• GPRC5D and other group 5 GPCRs have unusually short amino -terminal domains for class C receptors, and are therefore, predicted to be conformationally similar to class A receptors. In this regard they are unique, with sequence homology to class C GPCRs and predicted structural topology comparable to class A receptors. Functional consequence of GPRC5D activation has not been described and the ligand remains unknown.
• the gene has three exons and is located on chromosome 12p 13.3 in humans.
• GPRC5D receptor is highly conserved among various species and shares 92% identity with cynomolgus monkey GPRC5D.
• GPRC5D mRNA is predominantly expressed in all malignant plasma cells from MM patients (Atamaniuk J A et al,. Eur J Clin Invest, 42(9) 953-960; 2012; Frigyesi- blood and Cohen, et al., Hematology 18(6): 348-35; 2013). GPRC5D expression is variable among the patients and correlates well with plasma cell burden and genetic aberrations such as Rb-1 deletion (Atamaniuk J A et al., Eur J Clin Invest, 42(9) 953- 960; 2012).
• MM Multiple myeloma
• MM is the second most common hematological malignancy and constitutes 2% of all cancer deaths.
• MM is a heterogeneous disease and caused mostly by chromosome translocations inter alia t(l 1 ; 14),t(4; 14),t(8;14),del(13),del(17) (Drach et al., Blood. 1998;92(3):802-809, Gertz et al., Blood. 2005;106(8).2837-2840; Facon et al., Blood. 2001;97(6): 1566-1571).
• MM-affected patients can experience a variety of disease-related symptoms due to, bone marrow infiltration, bone destruction, renal failure, immunodeficiency, and the psychosocial burden of a cancer diagnosis. Based on people diagnosed with MM between 2009 and 2015, the 5-year relative survival rate for MM was approximately 51%. This highlights that MM is a difficult-to- treat disease where there are currently insufficient curative options.
• Relapsed and refractory MM constitutes a specific unmet medical need.
• Patients with relapsed and refractory disease are defined as those who achieve minor response or better then progress while on therapy or who experience progression within 60 days of their last therapy. Patients who progress after receiving both an immunomodulatory drug and proteasome inhibitor have limited options.
• Heavily pretreated patients often present with a compromised immune system, which can result in other disease conditions such as opportunistic infections and toxicities (e.g., myelosuppression, peripheral neuropathy, deep vein thrombosis) that persist from prior treatment.
• opportunistic infections and toxicities e.g., myelosuppression, peripheral neuropathy, deep vein thrombosis
• patients with advanced MM are often elderly and are susceptible to serious treatment-emergent adverse events (TEAEs) with continued exposure to these therapies.
• TEAEs treatment-emergent adverse events
• Selinexor BLENREP (belantamab mafodotin-blmf), recently approved Melfufen (melphalan flufenamide) administered in combination with dexamethasone, as well as recently approved Ide -cel (idecabtagene viceleucel, formerly termed bb2121) are licensed in the United States for this highly refractory disease setting. The remaining options for these patients are either entry into a clinical trial, or they can be offered retreatment with a prior treatment regimen (if the toxicity profile for retreatment permits).
• a method of treating a hematological malignancy such as multiple myeloma, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GPRC5DxCD3 bispecific antibody or antigen binding fragment thereof, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer therapy.
• the GPRC5DxCD3 bispecific antibody or antigen binding fragment thereof comprises a GPRC5D binding domain comprising the HCDR1 of SEQ ID NO: 4, the HCDR2 of SEQ ID NO: 5, the HCDR3 of SEQ ID NO: 6, the LCDR1 of SEQ ID NO: 7, the LCDR2 of SEQ ID NO: 8 and the LCDR3 of SEQ ID NO: 9, and a CD3 binding domain comprising the HCDR1 of SEQ ID NO: 14, the HCDR2 of SEQ ID NO: 15, the HCDR3 of SEQ ID NO: 16, the LCDR1 of SEQ ID NO: 17, the LCDR2 of SEQ ID NO: 18 and the LCDR3 of SEQ ID NO: 19.
• the GPRC5D binding domain comprises a heavy chain variable region (VH) having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 11, and the CD3 biding domain comprises a VH having the amino acid sequence of SEQ ID NO: 20 and a VL having the amino acid sequence of SEQ ID NO: 21.
• VH heavy chain variable region
• VL light chain variable region
• the CD3 biding domain comprises a VH having the amino acid sequence of SEQ ID NO: 20 and a VL having the amino acid sequence of SEQ ID NO: 21.
• the GPRC5DxCD3 bispecific antibody is of IgG4 isotype and comprises phenylalanine at position 405 and arginine at position 409 in a first heavy chain (HC1) and leucine at position 405 and lysine at position 409 in a second heavy chain (HC2).
• the GPRC5DxCD3 bispecific antibody further comprises proline at position 228, alanine at position 234 and alanine at position 235 in both the HC1 and the HC2.
• the GPRC5DxCD3 bispecific antibody comprises the HC1 having the amino acid sequence of SEQ ID NO: 12, a first light chain (LC1) having the amino acid sequence of SEQ ID NO: 13, the HC2 having the amino acid sequence of SEQ ID NO: 22 and a second light chain (LC2) having the amino acid sequence of SEQ ID NO: 23.
• the GPRC5DxCD3 bispecific antibody is talquetamab.
• the GPRC5DxCD3 bispecific antibody is administered intravenously or subcutaneously at a dose of about 0.2 pg/kg to about 1200 pg/kg.
• the GPRC5DxCD3 bispecific antibody is administered intravenously at a dose of about 0.2 pg/kg to about 500 pg/kg, preferably about 1 pg/kg to about 300 pg/kg, most preferably about 10 pg/kg to about 200 pg/kg, such as about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 pg/kg, or any value in between.
• the dose can be administered monthly, tri-weekly (i.e., one dose every three weeks), bi-weekly (i.e., one dose every other week), weekly, twice weekly (i.e., two doses every week).
• the GPRC5DxCD3 bispecific antibody is administered subcutaneously at a dose of about 0.5 pg/kg to about 2400 pg/kg, about 0.5 pg/kg to about 1200 pg/kg, or about 1 pg/kg to about 100 pg/kg, or about 10 pg/kg to about 800 pg/kg , such as about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 135, 150, 200, 250, 300, 350, 400, 405, 450, 500, 550, 600, 650, 700, 750, 800, 900, 950, 1000, 1050, 1100, 1150, 1200 pg/kg, or any value in between.
• the dose can be administered monthly, tri-weekly, bi-weekly, weekly, or twice weekly.
• the GPRC5DxCD3 bispecific antibody is administered subcutaneously at a dose of about 10 pg/kg to about 1000 pg/kg weekly, such as lat a dose of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 135, 150, 200, 250, 300, 350, 400, 405, 450, 500, 550, 600, 650, 700, 750, 800, 900, 950, 1000 pg/kg weekly.
• the GPRC5DxCD3 bispecific antibody is administered subcutaneously at a dose of about 100 pg/kg to about 2400 pg/kg biweekly, such as lat a dose of about 100, 135, 150, 200, 250, 300, 350, 400, 405, 450, 500, 550, 600, 650, 700, 750, 800, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300 or 2400 pg/kg, or any dose in between biweekly.
• the GPRC5DxCD3 bispecific antibody is administered for a time sufficient to achieve complete response, stringent complete response, very good partial response, partial response, minimal response or stable disease status, and can be continued until disease progression or lack of patient benefit.
• the GPRC5DxCD3 bispecific antibody is administered to achieve negative minimal residual disease (MRD) status, preferably negative MRD status defined as fewer than one tumor cell in 10' 6 bone marrow cells, as determined by next generation sequencing (NGS), or an overall response rate of at least 20%, such as at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or any value in between.
• MRD minimal residual disease
• NGS next generation sequencing
• the GPRC5DxCD3 bispecific antibody is administered to a subject in need thereof to result in an exposure of GPRC5DxCD3 bispecific antibody at a steady state mean Cmax of 10 to 25,000 ng/ml, such as 100 to 20,000 ng/ml or 1000-10,000 ng/ml, and a steady state mean AUCo-i4dof 1000 to 1,500,000 ng h/ml, such as 5000 to 1,000,000 ng h/ml or 10,000 to 1,000,000 ng h/mL.
• the prior anti-cancer therapy is selected from the group consisting of thalidomide, lenalidomide, pomalidomide, bortezomib, ixazomib, carfilzomib, panobinostat, pamidronate, zoledronic acid, daratumumab, elotuzumab, melphalan, selinexor, belantamab mafodotin-blmf, Venetoclax, CC-92480 (CELMoD (cereblon E3 ligase modulator) agent), CAR-T therapies, other BCMA-directed therapies, other CD38-directed therapies, and combinations of two or more thereof.
• CELMoD cereblon E3 ligase modulator
• the subject is relapsed or refractory to treatment with more than one prior anti-cancer therapies.
• the subject can be relapsed or refractory to 2-20 prior anti-cancer therapies, such as at least two, three, four, five, six, seven, eight, nine, ten or more prior anti-cancer therapies.
• the subject is a human.
• the subject has relapsed or refractory multiple myeloma or is intolerant to standard therapies.
• the subject can be previously treated with a B-cell maturation antigen (BCMA)-directed therapy.
• BCMA B-cell maturation antigen
• the method further comprises administering to the subject one or more additional anti-cancer therapies.
• the one or more additional anti-cancer therapies are selected from the group consisting of autologous stem cell transplants (ASCT), radiation, surgery, chemotherapeutic agents, CAR-T therapies, cellular therapies, immunomodulatory agents, targeted cancer therapies, and combinations of two or more thereof.
• ASCT autologous stem cell transplants
• the one or more additional anti-cancer therapies are selected from the group consisting of selinexor, belantamab mafodotin-blmf, isatuximab, venetoclax, lenalidomide, thalidomide, pomalidomide, bortezomib, carfilzomib, elotozumab, ixazomib, melphalan, dexamethasone, vincristine, cyclophosphamide, hydroxydaunorubicin, prednisone, rituximab, imatinib, dasatinib, nilotinib, bosutinib, ponatinib, bafetinib, saracatinib, tozasertib, danusertib, cytarabine, daunorubicin, idarubicin, mitoxantron
• Figure 1A shows a schematic example of potential escalation steps.
• Figure IB shows the study design of a phase 1 study with 184 patients in total, which includes an escalation study with weekly (QW) subcutaneous administration (SC) of 5- 800 pg/kg of talquetamab, or with intravenous administration (IV) of 0.3 - 180 pg/kg of talquetamab, with or without step-up dosing, wherein the step-up dosing contained 1-3 step-up doses administered to the patients within 1 week before a full dose, e.g., the SC of 405 pg/kg talquetamab was administered with step-up doses of 10 and 60 pg/kg within 1 week before the administration of the full dose.
• QW weekly
• SC subcutaneous administration
• IV intravenous administration
• Figure 3A is a graph showing induction of interleukin-2 receptor subunit alpha (IL2Ra) with SC dosing with the cut-off date for the analysis of 24 Oct 2020
• Figure 3B is a graph showing induction of programmed cell death protein 1 (PD-1)+ T cells with SC dosing with the cut-off date for the analysis of April 18, 2021.
• IL2Ra interleukin-2 receptor subunit alpha
• PD-1 programmed cell death protein 1
• Figure 4 is a bar chart showing the overall response rate for SC doses, (CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response).
• Figure 5A is a graph showing duration of response for IV doses with the cut-off date for the analysis of 24 Oct 2020
• Figure 5B is a graph showing duration of response for SC doses ranging from 45 to 800 pg/kg with the cut-off date for the analysis of April 18, 2021
• Figure 5C is a graph showing duration of response for SC at 405 pg/kg weekly
• FIGS 6A and 6B are graphs showing GPRC5D cell surface expression profile.
• Figure 7 is a graph showing talquetamab-mediated MM cell lysis. Incubation of HD peripheral blood MNCs + luciferase-transduced cell line (ratio 10:1) with serial dilutions of talquetamab, Bioluminescence Imaging read out after 48 hours.
• Figures 9A-9D are graphs showing impacts of pre-treatment and cytogenetic abnormalities on talquetamab-mediated lysis.
• Incubation of freshly isolated BM-MNCs with serial dilutions of talquetamab (n 45), FACS read out after 48 hours.
• RRMM: prior lines 3, 88% lenalidomide-refractory, 24% bortezomib-refractory.
• FIGS 10A-10C are graphs showing impact of tumor and immune characteristics by talquetamab. Samples were divided in groups based on the median group-value of the indicated variable.
• Figures 11A-11D are graphs showing impact of Treg on talquetamab efficacy.
• (B) Violet tracer labeled T-cells were incubated with or without Tregs for 5 days in the presence of anti-CD3/CD28 beads, proliferation was read out using flow cytometry (n 3).
• Figures 12A and 12B are graphs showing the impact of bone marrow stromal cells (BMSC) on talquetamab efficacy.
• BMSC bone marrow stromal cells
• FIG. 12A Luciferase-transduced MM cell lines were incubated with patient derived stromal cells (ratio 1:2) + HD PBMCs (PBMC:MM ratio 10:1) and serial dilutions of talquetamab for 48 hours.
• Stromal cells were placed directly in the well containing MM cells and PBMCs (direct) or in a transwell insert (indirect).
• Figures 13A-13C are graphs showing that patient- specific factors can determine response to T-cell redirectors targeting different agents.
• Figure 14 is a graph showing the maximum Cytokine Release Syndrome (CRS) Grade in patients treated with weekly (QW) subcutaneous (SC) administration of talquetamab during the study.
• RP2D stands for recommended Phase 2 dose, which was administered at 405 pg/kg, with step-up doses of 10 and 60 pg/kg; CRS was graded according to Lee et al. Blood. 2014.124: 188.
• antibodies as used herein is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen binding fragments, multispecific antibodies, such as bispecific, trispecific, tetraspecific etc., dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity.
• “Full length antibodies” are comprised of two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds as well as multimers thereof (e.g. IgM).
• Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (comprised of domains CHI, hinge, CH2 and CH3).
• Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL).
• the VH and the VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR).
• CDR complementarity determining regions
• FR framework regions
• Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-to-carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
• Immunoglobulins can be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence.
• IgA and IgG are further sub-classified as the isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4.
• Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.
• antigen binding fragment or “antigen binding domain” as used herein refer to a portion of an immunoglobulin molecule that binds an antigen.
• Antigen binding fragments can be synthetic, enzymatically obtainable or genetically engineered polypeptides and include the VH, the VL, the VH and the VL, Fab, F(ab')2, Fd and Fv fragments, domain antibodies (dAb) consisting of one VH domain or one VL domain, shark variable IgNAR domains, camelized VH domains, minimal recognition units consisting of the amino acid residues that mimic the CDRs of an antibody, such as FR3- CDR3-FR4 portions, the HCDR1, the HCDR2 and/or the HCDR3 and the LCDR1, the LCDR2 and/or the LCDR3.
• VH and VL domains can be linked together via a synthetic linker to form various types of single chain antibody designs where the VH/VL domains can pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Patent Publ. Nos. W01998/44001; WO1988/01649; WO1994/13804; and W01992/01047.
• scFv single chain Fv
• bispecific refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen.
• the bispecific antibody can have cross -reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca cynomolgus (cynomolgus, cyno) or Pan troglodytes, or can bind an epitope that is shared between two or more distinct antigens.
• binds or “binds specifically” or derivatives thereof when used in the context of antibodies, or antibody fragments, represents binding via domains encoded by immunoglobulin genes or fragments of immunoglobulin genes to one or more epitopes of a protein of interest, without preferentially binding other molecules in a sample containing a mixed population of molecules.
• an antibody binds to a cognate antigen with a Kd of less than about IxlO' 6 M, as measured by a surface plasmon resonance assay or a cell-binding assay.
• Phrases such as “[antigen]-specific” antibody e.g., GPRC5D- specific antibody
• CH3 region or “CH3 domain” as used herein refers to the CH3 region of an immunoglobulin.
• the CH3 region of human IgGl antibody corresponds to amino acid residues 341-446.
• the CH3 region can also be any of the other antibody isotypes as described herein.
• a “GPRC5D*CD3 antibody” is a multispecific antibody, optionally a bispecific antibody, which comprises two different antigen -binding regions, one of which binds specifically to the antigen GPRC5D and one of which binds specifically to CD3.
• a multispecific antibody can be a bispecific antibody, diabody, or similar molecule (see for instance PNAS US A 90(14), 6444-8 (1993) for a description of diabodies).
• the bispecific antibodies, diabodies, and the like, provided herein can bind any suitable target in addition to a portion of GPRC5D.
• the term “bispecific antibody” is to be understood as an antibody having two different antigen-binding regions defined by different antibody sequences. This can be understood as different target binding but includes as well binding to different epitopes in one target.
• G-protein coupled receptor family C group 5 member D and “GPRC5D” specifically include the human GPRC5D protein, for example as described in SEQ ID NO: 1 or GenBank Accession No. BC069341, NCBI Reference Sequence: NP_061124.1 and UniProtKB/Swiss-Prot Accession No. Q9NZD1 (see also Brauner-Osbome, H. et al. 2001, Biochim. Biophys. Acta 1518, 237-248).
• CD3 refers to the human CD3 protein multi-subunit complex.
• the CD3 protein multi-subunit complex is composed to 6 distinctive polypeptide chains. These include a CD3y chain (SwissProt P09693), a CD38 chain (SwissProt P04234), two CD3s chains (SwissProt P07766), and one CD3 chain homodimer (SwissProt 20963), and which is associated with the T cell receptor a and 0 chain.
• CD3 includes any CD3 variant, isoform and species homolog which is naturally expressed by cells (including T cells) or can be expressed on cells transfected with genes or cDNA encoding those polypeptides, unless noted.
• human CD3 epsilon can comprise the amino acid sequence of SEQ ID NO: 2.
• SEQ ID NO: 3 shows the extracellular domain of a human CD3 epsilon.
• cancer refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream.
• a “cancer” or “cancer tissue” can include a tumor.
• CDR complementarity determining regions
• CDR CDR
• HCDR1 CDR1
• HCDR2 CDR3
• LCDR1 CDR2
• LCDR3 CDR3
• the term “enhance” or “enhanced” as used herein refers to enhancement in one or more functions of a test molecule when compared to a control molecule or a combination of test molecules when compared to one or more control molecules.
• Exemplary functions that can be measured are tumor cell killing, T cell activation, relative or absolute T cell number, Fc-mediated effector function (e.g. ADCC, CDC and/or ADCP) or binding to an Fey receptor (FcyR) or FcRn.
• “Enhanced” can be an enhancement of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or a statistically significant enhancement.
• Fc gamma receptor FcyR
• FcyR Fc gamma receptor
• human antibody refers to an antibody that is optimized to have minimal immune response when administered to a human subject. Variable regions of human antibody are derived from human immunoglobulin sequences. If human antibody contains a constant region or a portion of the constant region, the constant region is also derived from human immunoglobulin sequences. Human antibody comprises heavy and light chain variable regions that are “derived from” sequences of human origin if the variable regions of the human antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes. Such exemplary systems are human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice or rats carrying human immunoglobulin loci.
• Human antibody typically contains amino acid differences when compared to the immunoglobulins expressed in humans due to differences between the systems used to obtain the human antibody and human immunoglobulin loci, introduction of somatic mutations or intentional introduction of substitutions into the frameworks or CDRs, or both.
• “human antibody” is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in amino acid sequence to an amino acid sequence encoded by human germline immunoglobulin or rearranged immunoglobulin genes.
• human antibody can contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., (2000) J Mol Biol 296:57-86, or synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, for example as described in Shi et al., (2010) J Mol Biol 397:385-96, and in Int. Patent Publ. No. W02009/085462.
• Antibodies in which at least one CDR is derived from a non-human species are not included in the definition of “human antibody”.
• humanized antibody refers to an antibody in which at least one CDR is derived from non-human species and at least one framework is derived from human immunoglobulin sequences. Humanized antibody can include substitutions in the frameworks so that the frameworks cannot be exact copies of expressed human immunoglobulin or human immunoglobulin germline gene sequences.
• isolated refers to a homogenous population of molecules (such as synthetic polynucleotides or a protein such as an antibody) which have been substantially separated and/or purified away from other components of the system the molecules are produced in, such as a recombinant cell, as well as a protein that has been subjected to at least one purification or isolation step.
• molecules such as synthetic polynucleotides or a protein such as an antibody
• isolated antibody refers to an antibody that is substantially free of other cellular material and/or chemicals and encompasses antibodies that are isolated to a higher purity, such as to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.
• the term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogenous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known alterations such as removal of C-terminal lysine from the antibody heavy chain or post- translational modifications such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation.
• Monoclonal antibodies typically bind one antigenic epitope.
• a bispecific monoclonal antibody binds two distinct antigenic epitopes.
• Monoclonal antibodies can have heterogeneous glycosylation within the antibody population.
• Monoclonal antibody can be monospecific or multispecific such as bispecific, monovalent, bivalent or multivalent.
• mutation refers to an engineered or naturally occurring alteration in a polypeptide or polynucleotide sequence when compared to a reference sequence. The alteration can be a substitution, insertion or deletion of one or more amino acids or polynucleotides.
• multispecific refers to an antibody that specifically binds at least two distinct antigens or at least two distinct epitopes within the same antigen. Multispecific antibody can bind for example two, three, four or five distinct antigens or distinct epitopes within the same antigen.
• Negative minimal residual disease status was determined using next generation sequencing (NGS).
• composition refers to composition that comprises an active ingredient and a pharmaceutically acceptable carrier.
• pharmaceutically acceptable carrier or “excipient” as used herein refers to an ingredient in a pharmaceutical composition, other than the active ingredient, which is nontoxic to a subject.
• recombinant refers to DNA, antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means when segments from different sources are joined to produce recombinant DNA, antibodies or proteins.
• the term “reduce” or “reduced” as used herein refers to a reduction in one or more functions of a test molecule when compared to a control molecule or a combination of test molecules when compared to one or more control molecules.
• Exemplary functions that can be measured are tumor cell killing, T cell activation, relative or absolute T cell number, Fc-mediated effector function (e.g. ADCC, CDC and/or ADCP) or binding to an Fey receptor (FcyR) or FcRn.
• “Reduced” can be a reduction of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or a statistically significant enhancement.
• refractory refers to a cancer that is unresponsive to an anti-cancer therapy.
• relapsed refers to a cancer that responded to a treatment but then returns after the treatment.
• subject as used herein includes any human or nonhuman animal.
• “Nonhuman animal” includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. Except when noted, the terms “patient” or “subject” are used interchangeably.
• T cell redirecting therapeutic refers to a molecule containing two or more binding regions, wherein one of the binding regions specifically binds a cell surface antigen on a target cell or tissue and wherein a second binding region of the molecule specifically binds a T cell antigen.
• cell surface antigen include a tumor associated antigen, such as GPRC5D.
• T cell antigens include, e.g., CD3. This dual/multi-target binding ability of a T cell redirecting therapeutic recruits T cells to a target cell or tissue, such as that having a tumor associated antigen, leading to the eradication of the target cell or tissue.
• therapeutically effective amount refers to an amount effective, at doses and for periods of time necessary, to achieve a desired therapeutic result.
• a therapeutically effective amount can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that include, for example, improved well-being of the patient.
• treat refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder.
• beneficial or desired clinical results include alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
• Treatment can also mean prolonging survival as compared to expected survival if a subject was not receiving treatment.
• Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
• tumor cell or a “cancer cell” as used herein refers to a cancerous, pre- cancerous or transformed cell, either in vivo, ex vivo, or in tissue culture, that has spontaneous or induced phenotypic changes. These changes do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic nucleic acid, uptake of exogenous nucleic acid or it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene.
• Transformation/cancer is exemplified by morphological changes, immortalization of cells, aberrant growth control, foci formation, proliferation, malignancy, modulation of tumor specific marker levels, invasiveness, tumor growth in suitable animal hosts such as nude mice, and the like, in vitro, in vivo, and ex vivo.
• the numbering of amino acid residues in the antibody constant region throughout the specification is according to the EU index as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991), unless otherwise explicitly stated.
• Antibody constant chain numbering can be found for example at ImMunoGeneTics website, at IMGT Web resources at IMGT Scientific charts.
• GPRC5D Overexpression of GPRC5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma (see e.g., Atamaniuk el al., E r. J. Clin. Invest. 42:953-960(2012)).
• This exclusive expression of GPRC5D on the plasma-cell lineage designates it as an ideal target for antimyeloma antibodies.
• Anti-GPRC5D antibodies and bispecific antibodies against GPRC5D and CD3 are described, e.g., in U.S. Patent No. 10,562,968, the content of which is incorporated herein by reference in its entirety.
• the invention is based, at least in part, on the finding that a GPRC5DxCD3 bispecific antibody, such as talquetamab, can be used to treat a hematological malignancy, such as multiple myeloma in subjects in need thereof, preferably subjects that are relapsed or refractory to treatment with a prior anti-cancer therapy.
• a GPRC5DxCD3 bispecific antibody such as talquetamab
• the invention relates to a method of treating a hematological malignancy, such as multiple myeloma, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GPRC5DxCD3 bispecific antibody to treat the hematological malignancy, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer therapy.
• a hematological malignancy such as multiple myeloma
• bispecific antibody formats include formats described herein and recombinant IgG-like dual targeting molecules, wherein the two sides of the molecule each contain the Fab fragment or part of the Fab fragment of at least two different antibodies; IgG fusion molecules, wherein full length IgG antibodies are fused to an extra Fab fragment or parts of Fab fragment; Fc fusion molecules, wherein single chain Fv molecules or stabilized diabodies are fused to heavy -chain constant-domains, Fc-regions or parts thereof; Fab fusion molecules, wherein different Fab-fragments are fused together; ScFv- and diabody-based and heavy chain antibodies (e.g., domain antibodies, nanobodies) wherein different single chain Fv molecules or different diabodies or different heavy-chain antibodies (e.g.
• bispecific formats include dual targeting molecules include Dual Targeting (DT)-Ig (GSK/Domantis), Two-in-one Antibody (Genentech) and mAb2 (F-Star), Dual Variable Domain (DVD)-Ig (Abbott), DuoBody (Genmab), Ts2Ab (Medlmmune/AZ) and BsAb (Zymogenetics), HERCULES (Biogen personal) and TvAb (Roche), ScFv/Fc Fusions (Academic Institution), SCORPION (Emergent BioSolutions/Trubion, Zymogenetics/BMS) and Dual Affinity Retargeting Technology (Fc-DART) (MacroGenics), F(ab)2 (Medarex/ AMGEN), Dual-Action or Bis-Fab (Genentech), Dock-and-Lock (DNL) (Immun
• a GPRC5DxCD3 bispecific antibody useful for the invention comprises a GPRC5D binding domain comprising a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 5, a HCDR3 of SEQ ID NO: 6, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO: 7, a LCDR2 of SEQ ID NO: 8 and a LCDR3 of SEQ ID NO: 9.
• HCDR1 heavy chain complementarity determining region 1
• LCDR1 light chain complementarity determining region 1
• a GPRC5DxCD3 bispecific antibody further comprises a CD3 binding domain comprising a HCDR1 of SEQ ID NO: 14, a HCDR2 of SEQ ID NO: 15, a HCDR3 of SEQ ID NO: 16, a LCDR1 of SEQ ID NO: 17, a LCDR2 of SEQ ID NO: 18, and a LCDR3 of SEQ ID NO: 19.
• references to residue numbers in the variable domain of antibodies means residue numbering by the Kabat numbering system.
• references to residue numbers in the constant domain of antibodies means residue numbering by the EU numbering system.
• a GPRC5DxCD3 bispecific antibody useful for the invention comprises a GPRC5D binding domain having a heavy chain variable region (VH) of SEQ ID NO: 10 and a light chain variable region (VL) of SEQ ID NO: 11, and a CD3 binding domain having a VH of SEQ ID NO: 20 and a VL of SEQ ID NO: 21.
• a GPRC5DxCD3 bispecific antibody useful for the invention is of IgGl, IgG2, IgG3 or IgG4 isotype.
• the bispecific antibody is of IgG4 isotype.
• An exemplary wild-type IgG4 Fc region comprises the amino acid sequence of SEQ ID NO: 24.
• a GPRC5DxCD3 bispecific antibody useful for the invention can be of any allotype. It is expected that allotype has no influence on properties of the bispecific antibodies, such as binding or Fc-mediated effector functions. Immunogenicity of therapeutic antibodies is associated with increased risk of infusion reactions and decreased duration of therapeutic response (Baert et al., (2003) N Engl J Med 348:602- 08). The extent to which therapeutic antibodies induce an immune response in the host can be determined in part by the allotype of the antibody (Stickler et al., (2011) Genes and Immunity 12:213-21). Antibody allotype is related to amino acid sequence variations at specific locations in the constant region sequences of the antibody. Table 2 shows exemplary IgGl, IgG2 and IgG4 allotypes.
• a GPRC5DxCD3 bispecific antibody useful for the invention comprises one or more Fc substitutions that reduces binding of the bispecific antibody to a Fey receptor (FcyR) and/or reduces Fc effector functions such as Clq binding, complement dependent cytotoxicity (CDC), antibody -dependent cell-mediated cytotoxicity (ADCC) or phagocytosis (ADCP).
• FcyR Fey receptor
• Fc effector functions such as Clq binding, complement dependent cytotoxicity (CDC), antibody -dependent cell-mediated cytotoxicity (ADCC) or phagocytosis
• CDC complement dependent cytotoxicity
• ADCC antibody -dependent cell-mediated cytotoxicity
• ADCP phagocytosis
• Fc positions that can be substituted to reduce binding of the Fc to the activating FcyR and subsequently to reduce effector function include, but are not limited to, substitutions L234A/L235A on IgGl, V234A/G237A/P238S/H268A/V309L/A330S /P331S on IgG2, F234A/L235A on IgG4, S228P/F234A/ L235A on IgG4, N297A on all Ig isotypes, V234A/G237A on IgG2, K214T/E233P/ L234V/L235A/G236- deleted/A327G/P331A/D365E/L358M on IgGl, H268Q/V309L/ A330S/P331S on IgG2, S267E/L328F on IgGl, L234F/L235E/D265A on IgGl
• Fc substitutions that can be used to reduce CDC include, but are not limited to a K322A substitution. Substitutions, such as S228P substitution, can further be made in IgG4 antibodies to enhance IgG4 stability.
• the GPRC5DxCD3 bispecific antibody can comprise one or more asymmetric substitutions in a first CH3 domain or in a second CH3 domain, or in both the first CH3 domain and the second CH3 domain.
• the one or more asymmetric substitutions can include, but are not limited to, those selected from the group consisting of F405L/K409R, wild-type/F405L_R409K, T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_L368A_Y407V, L351 Y_F405A_Y407V/T394W, T366I_K392M_T394W/F405A_Y407V, T366L_K392M_T394W/F405A_Y407V, L351 Y_Y407A/T366A_K409F, L351 Y_Y407A/T366A_K409F, L
• a GPRC5DxCD3 bispecific antibody useful for the invention is of IgG4 isotype and comprises phenylalanine at position 405 and arginine at position 409 in a first heavy chain (HC1) and leucine at position 405 and lysine at position 409 in a second heavy chain (HC2).
• a GPRC5DxCD3 bispecific antibody useful for the invention further comprises proline at position 228, alanine at position 234 and alanine at position 235 in both the HC1 and the HC2.
• a GPRC5DxCD3 bispecific antibody useful for the invention comprises the HC1 of SEQ ID NO: 12, a first light chain (LC1) of SEQ ID NO: 13, the HC2 of SEQ ID NO: 22, and a second light chain (LC2) of SEQ ID NO: 23, wherein the LC1 binds to the HC1, the LC2 binds to the HC2, and the HC1 is linked to the HC2.
• a GPRC5DxCD3 bispecific antibody useful for the invention is talquetamab, having the HC1 of SEQ ID NO: 12, LC1 of SEQ ID NO: 13, HC2 of SEQ ID NO: 22 and LC2 of SEQ ID NO: 23. Cancers
• Methods of the application can be used to treat a cancer, preferably, a hematological malignancy, more preferably a relapsed or refractory hematological malignancy.
• hematological malignancy can be selected from multiple myeloma, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), Waldenstrom’s macroglobulinema, plasma cell leukemia, light chain amyloidosis (AL), precursor B-cell lymphoblastic leukemia, precursor B-cell lymphoblastic leukemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), B cell malignancy, chronic myeloid leukemia (CML), hairy cell leukemia (HCL), blastic plasmacytoid dendritic cell neoplasm, Hodgkin’s lymphoma, non
• the hematological malignancy is multiple myeloma.
• the subject has a newly diagnosed multiple myeloma.
• the subject is relapsed or refractory to treatment with a prior anticancer therapeutic, such as a therapeutic used to treat multiple myeloma or other hematological malignancies.
• the subject is refractory or relapsed to one or more prior anti-cancer treatments or therapies.
• prior anti -cancer treatments or therapies include, without limitation, THALOMID® (thalidomide), REVLIMID® (lenalidomide), POMALYST® (pomalidomide), VELCADE® (bortezomib), NINLARO (ixazomib), KYPROLIS® (carfilzomib), FARAD YK® (panobinostat), AREDIA® (pamidronate), ZOMETA® (zoledronic acid), DARZALEX® (daratumumab), EMPLICITI® (elotuzumab), melphalan, Xpovio® (Selinexor), BLENREP (belantamab mafodotin-blmf), Venclexta® (Venetoclax), CAR-T therapies, other BCMA-directed therapies, other CD38-directed
• relapse or refractory nature of the disease According to NCCN Guidelines, “clinical relapse” are defined as having one of more of the following occurred: there are direct signs of cancer growth, signs of organ damage, an increase in the number of size (at least 50% larger) of plasmacytomas or bone lesions, increased calcium levels, an increase in creatinine levels in blood, or a decrease in the number of red blood cells, and “relapse from complete response” is defined as having one or more of the following occurred in a patient who had a complete response: a return of M-proteins in blood or urine, or other signs of myeloma but not meeting the criteria for a clinical relapse progressive disease.
• the multiple myeloma is a high-risk multiple myeloma. Subjects with high-risk multiple myeloma are known to relapse early and have poor prognosis and outcome.
• Subjects can be classified as having high-risk multiple myeloma if they have one or more of the following cytogenetic abnormalities: t(4; 14)(p 16;q32), t(14;16)(q32;q23), dell7p, IqAmp, t(4; 14)(pl6;q32) and t(14;16)(q32;q23), t(4; 14)(p 16;q32) and dell7p, t( 14; 16)(q32;q23) and dell7p, or t(4; 14)(p 16;q32), t( 14; 16)(q32;q23) and dell7p.
• the subject having the high-risk multiple myeloma can have one or more chromosomal abnormalities comprising: t(4;14)(pl6;q32), t(14;16)(q32;q23), dell7p, IqAmp, t(4;14)(pl6;q32) and t(14;16)(q32;q23), t(4;14)(pl6;q32) and dell7p, t(14;16)(q32;q23) and dell7p; or t(4;14)(pl6;q32), t(14;16)(q32;q23) and dell7p, or any combination thereof.
• the cytogenetic abnormalities can be detected for example by fluorescent in situ hybridization (FISH).
• FISH fluorescent in situ hybridization
• an oncogene is translocated to the IgH region on chromosome 14q32, resulting in dysregulation of these genes.
• t(4;14)(pl6;q32) involves translocation of fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain containing protein (MMSET) (also called WHSC1/NSD2)
• t(14;16)(q32;q23) involves translocation of the MAF transcription factor C-MAF.
• Deletion of 17p (dell7p) involves loss of the p53 gene locus.
• Chromosomal rearrangements can be identified using well known methods, for example fluorescent in situ hybridization, karyotyping, pulsed field gel electrophoresis, or sequencing.
• a GPRC5DxCD3 bispecific antibody useful for the invention can be formulated as a pharmaceutical composition comprising about 1 mg/mL to about 200 mg/mL antibody.
• the pharmaceutical composition further comprises one or more excipients.
• the one or more excipients include, but are not limited to, a buffering agent, a sugar, a surfactant, a chelator, metal ion scavenger, or any combination thereof.
• the pharmaceutical composition comprises: about 1 mg/mL to about 200 mg/mL of a GPRC5DxCD3 bispecific antibody, such as about 1 mg/ml, about 5 mg/ml, about 10 mg/ml, about 15 mg/ml, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, about 45 mg/mL, about 50 mg/mL, about 60 mg/mL, about 70 mg/mL, about 80 mg/mL, about 90 mg/mL, about 100 mg/mL, about 110 mg/mL, about 120 mg/mL, or any value in between, of the GPRC5DxCD3 bispecific antibody; about 5 mM to about 20 mM buffering agent, such as about 5 mM, about 10 mM, about 15 mM, about 20 mM, or any value in between, sodium phosphate, KH2PO4, sodium acetate, histidine, or sodium
• the pharmaceutical composition disclosed herein may further comprise about 0.1 mg/mL to about 5 mg/mL amino acid, such as about 0.1 mg/mL, about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, about 0.6 mg/mL, about 0.7 mg/mL, about 0.8 mg/mL, about 0.9 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, or any value in between, methionine or arginine.
• amino acid such as about 0.1 mg/mL, about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, about 0.6 mg/mL, about 0.7 mg/mL, about 0.8 mg/mL, about 0.9 mg/mL, about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/
• a pharmaceutical composition useful for the invention comprises 5 mg/ml to 20 mg/ml, such as 5, 10, 15, 20 mg/ml, or any value in between, of a GPRC5DxCD3 bispecific antibody, such as talquetamab, 20 mM sodium phosphate, 10% weight/volume (w/v) sucrose, 0.06% (w/v) PS80, and 25 pg/mL EDTA at pH 5.4.
• a GPRC5DxCD3 bispecific antibody such as talquetamab, 20 mM sodium phosphate, 10% weight/volume (w/v) sucrose, 0.06% (w/v) PS80, and 25 pg/mL EDTA at pH 5.4.
• the pharmaceutical composition disclosed herein comprises 5 mg/ml to 20 mg/ml, such as 5, 10, 15, 20 mg/ml, or any value in between, of a GPRC5DxCD3 bispecific antibody, such as talquetamab, 10 to 15 mM sodium acetate, 8% (w/v) sucrose, 0.04% (w/v) PS20, and 20 pg/mL EDTA at pH 5.2.
• a GPRC5DxCD3 bispecific antibody such as talquetamab, 10 to 15 mM sodium acetate, 8% (w/v) sucrose, 0.04% (w/v) PS20, and 20 pg/mL EDTA at pH 5.2.
• the pharmaceutical composition disclosed herein comprises 5 mg/ml to 20 mg/ml, such as 5, 10, 15, 20 mg/ml, or any value in between, of a GPRC5DxCD3 bispecific antibody, such as talquetamab, 15 mM KH2PO4, 10% (w/v) cellobiose, 0.05% (w/v) PS20, and 25 pg/mL EDTA at pH 5.1.
• a GPRC5DxCD3 bispecific antibody such as talquetamab, 15 mM KH2PO4, 10% (w/v) cellobiose, 0.05% (w/v) PS20, and 25 pg/mL EDTA at pH 5.1.
• the pharmaceutical composition disclosed herein comprises 2 mg/ml to 40 mg/ml, such as 5, 10, 15, 20, 30, 40 mg/ml, or any value in between, of a GPRC5DxCD3 bispecific antibody, such as talquetamab, 15 mM Histidine, 8% (w/v) sucrose, 0.04% (w/v) PS20, and 20 pg/mL EDTA at pH 5.2.
• a GPRC5DxCD3 bispecific antibody such as talquetamab, 15 mM Histidine, 8% (w/v) sucrose, 0.04% (w/v) PS20, and 20 pg/mL EDTA at pH 5.2.
• the GPRC5DxCD3 bispecific antibody can be administered to the subject by intravenous infusion or subcutaneous injection.
• the dose of a GPRC5DxCD3 bispecific antibody given to a subject having a hematological malignancy, such as multiple myeloma, is sufficient to alleviate or at least partially arrest the disease being treated.
• Examples of the dosages useful for the invention include from about 0.2 pg/kg to about 1200 pg/kg, e.g. about 0.5 pg/kg to 100 pg/kg, about 1 pg/kg to about 800 pg/kg, about 1 pg/kg to about 500 pg/kg of the antibody.
• Suitable doses include, e.g., about 0.2 pg/kg, about 0.6 pg/kg, about 1.2 pg/kg, about 2.4 pg/kg, about 4.8 pg/kg, about 9.6 pg/kg, about 19.2 pg/kg, about 20 pg/kg, about 38.4 pg/kg, about 40 pg/kg, about 57.6 pg/kg, about 60 pg/kg, about 80 pg/kg, about 120 pg/kg, about 180 pg/kg, about 240 pg/kg, about 270 pg/kg, about 300 pg/kg, about 460, about 720 pg/kg, about 800 pg/kg, about 1000 pg/kg, about 1200 pg/kg, about 1600 pg/kg, about 2000 pg/kg, about 2400 pg/kg, or any dose in between.
• a GPRC5DxCD3 bispecific antibody is administered to a subject intravenously at a dose of about 0.2 pg/kg to about 200 pg/kg, or about 0.5 pg/kg to about 180 pg/kg, or about 1 pg/kg to about 150 pg/kg, or about 5 pg/kg to about 100 pg/kg, or about 10 pg/kg to about 70 pg/kg.
• Examples of the dose for intravenous administration include, e.g., about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 pg/kg, or any value in between.
• the dose can be intravenously administered monthly, tri-weekly, bi-weekly, weekly, twice weekly, or any frequency in between.
• the GPRC5DxCD3 bispecific antibody is administered to a subject subcutaneously at a dose of about 0.5 pg/kg to about 2400 pg/kg, about 0.5 pg/kg to about 1200 pg/kg, or about 1 pg/kg to about 800 pg/kg, or about 10 pg/kg to about 500 pg/kg.
• Examples of the dose for subcutaneous administration include, e.g., about 10, 50, 100, 135, 150, 200, 250, 300, 350, 400, 405, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150 pg/kg, 1200 pg/kg, 1600 pg/kg, 2000 pg/kg, 2400 pg/kg, or any value in between.
• the dose can be subcutaneously administered monthly, tri-weekly, bi-weekly, weekly, twice weekly, or any frequency in between.
• a fixed unit dose of a GPRC5DxCD3 bispecific antibody can also be given, for example, at 50, 100, 200, 500, or 1000 mg, or any value in between, per administration.
• the dose can also be based on the patient's surface area, e.g., 500, 400, 300, 250, 200, or 100 mg/m 2 , or any value in between.
• Multiple doses can be administered to treat a hematological malignancy, such as a multiple myeloma, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more doses can be given.
• a GPRC5DxCD3 bispecific antibody can be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months, or longer. Repeated courses of treatment are also possible, as is chronic administration.
• the repeated administration can be at the same dose or at a different dose.
• a GPRC5DxCD3 bispecific antibody can be administered at a first dose for a first time period, followed by administration at a second dose for a second time period.
• the GPRC5DxCD3 bispecific antibody is administered every two weeks (i.e., bi-weekly) for a certain number of weeks, followed by administration at a second dose every week (i.e., weekly) for an additional certain number of weeks, followed by administration at a third dose every week for an additional certain number of weeks.
• a GPRC5DxCD3 bispecific antibody can be administered, such as, once a week for a period needed.
• the GPRC5DxCD3 bispecific antibody can be provided every 2 to 4 days (e.g., for the step up dosses) and then weekly, biweekly, triweekly or monthly (e.g., for the full dose) in an amount of about 0.2 pg/kg to about 2400 pg/kg, 0.2 pg/kg to about 1000 pg/kg, e.g.
• a GPRC5DxCD3 bispecific antibody is administered intravenously twice a week, once a week, once every two weeks, once every three weeks, monthly or any frequency in between in an amount of about 0.3 pg/kg, about 0.5 pg/kg, about 1.0 pg/kg, about 1.5 pg/kg, about 2.25 pg/kg, about 2.5 pg/kg, about 2.75 pg/kg, about 3 pg/kg, about 3.25 pg/kg, about 3.38 pg/kg, about 3.5 pg/kg, about 3.75 pg/kg, about 4 pg/kg, about 4.25 pg/kg, about 4.5 pg/kg, about 4.75 pg/kg, about 5pg/kg, about 7.5 pg/kg, about 10 pg/kg, about 11.25 pg/kg, about 20 pg/kg, about 30 pg/kg, about 40 pg/kg, about 50 pg/kg, about
• a GPRC5DxCD3 bispecific antibody is administered subcutaneously twice a week, once a week, once every two weeks, once every three weeks, monthly or any frequency in between in an amount of about 0.3 gg/kg, about 0.6 gg/kg, about 1.2 gg/kg, about 1.5 gg/kg, about 2.5 gg/kg, about 5 gg/kg, about 10 gg/kg, about 15 gg/kg, about 20 gg/kg, about 25 gg/kg, about 30 gg/kg, about 40 gg/kg, about 45 gg/kg, about 50 gg/kg, about 55 gg/kg, about 60 gg/kg, about 80 gg/kg, about 120 gg/kg, about 135 gg/kg, about 180 gg/kg, about 240 gg/kg, about 270 gg/kg, about 300 gg/kg, about 350 gg/kg, about 400 gg/kg, about 405 gg/kg, about 720 gg/kg, about 800 gg
• a GPRC5DxCD3 bispecific antibody is administered in one or more priming administrations that gradually increase the dose levels.
• the priming dose strategies can be utilized effectively for bispecific T cell engager antibodies such as a GPRC5DxCD3 bispecific antibody, due to the potential for these antibodies to cause more pronounced acute toxicities with the initial dose.
• One or more priming doses can be used to ensure safety, obtain the desired T cell adaptation effect, decrease cytokine levels, and decrease the incidence of symptomatic cytokine release syndrome (CRS) in a majority of treated subjects.
• Priming dose(s) is administered prior to Day 1 of the bi-weekly, weekly, triweekly or monthly dose schedules with higher dose.
• a GPRC5DxCD3 bispecific antibody is administered intravenously at a step-up (or “priming”) dose, followed by weekly, biweekly, triweekly, or monthly administration at a higher dose intravenously or subcutaneously.
• the GPRC5DxCD3 bispecific antibody can be administered intravenously at a priming dose of about 0.3 gg/kg, about 0.5 gg/kg, about 0.6 gg/kg, about 1.0 gg/kg, about 1.5 gg/kg, about 2.25 gg/kg, about 2.4 gg/kg, about 3.0 gg/kg, about 3.38 gg/kg, about 3.5 gg/kg, about 3.75 gg/kg, about 4 gg/kg, about 4.25 gg/kg, about 4.5 gg/kg, about 4.75 gg/kg, about 5gg/kg , or any dose in between.
• the GPRC5DxCD3 bispecific antibody can be administered weekly, biweekly, triweekly or monthly intravenously at a higher dose, such as about 1.0 gg/kg, about 1.5 gg/kg, about 2.25 gg/kg, about 2.5 gg/kg, about 2.75 gg/kg, about 3 gg/kg, about 3.25 gg/kg, about 3.38 gg/kg, about 3.5 gg/kg, about 3.75 gg/kg, about 4 gg/kg, about 4.25 gg/kg, about 4.5 gg/kg, about 4.75 gg/kg, about 5gg/kg, about 7.5 gg/kg, about 10 gg/kg, about 11.25 gg/kg, about 20 gg/kg, about 30 pg/kg, about 40 pg/kg, about 50 pg/kg, about 60 pg/kg, about 80 pg/kg, about 120 pg/kg, about 180 pg/kg, about 200 pg/kg, or any dose in
• the GPRC5DxCD3 bispecific antibody is administered weekly, biweekly, triweekly or monthly subcutaneously at a higher dose, such as about 1.2 pg/kg, about 1.5 pg/kg, about 2.5 pg/kg, about 5 pg/kg, about 10 pg/kg, about 15 pg/kg, about 20 pg/kg, about 25 pg/kg, about 30 pg/kg, about 40 pg/kg, about 45 pg/kg, about 50 pg/kg, about 55 pg/kg, about 60 pg/kg, about 80 pg/kg, about 120 pg/kg, about 135 pg/kg, about 180 pg/kg, about 240 pg/kg, about 270 pg/kg, about 300 pg/kg, about 350 pg/kg, about 400 pg/kg, about 405 pg/kg, about 720 pg/kg, about 800
• a GPRC5DxCD3 bispecific antibody is administered intravenously at a first step-up dose, followed by administration at a second higher step-up dose, followed by weekly, biweekly, triweekly or monthly administration at a third, higher dose.
• the GPRC5DxCD3 bispecific antibody can be administered intravenously at a step-up dose of about 0.5 pg/kg, about 1.0 pg/kg, about 1.5 pg/kg, about 2.25 pg/kg, about 2.5 pg/kg, about 2.75 pg/kg, about 3.0 pg/kg, about 3.25 pg/kg, about 3.5 pg/kg, or any dose in between, followed by intravenous administration at a second step-up dose of about 5 pg/kg, about 7.5 pg/kg, about 10 pg/kg, about 12.5 pg/kg, about 15 pg/kg, or any dose in between, followed by weekly intravenous administration at a dose of about 15 pg/kg, about 20 pg/kg, about 30 pg/kg, about 40 pg/kg, about 50 pg/kg, about 60 pg/kg, about 80 pg/kg, about 120 pg/kg, about 180
• the GPRC5DxCD3 bispecific antibody is administered intravenously at a first step-up dose, followed by administration at a second higher step-up dose, followed by administration at a third higher step-up dose, followed by weekly, biweekly, triweekly or monthly administration at a fourth, higher dose.
• the GPRC5DxCD3 bispecific antibody can be administered intravenously at a first step-up dose of about 0.3 pg/kg, about 0.6 pg/kg, about 1.2 pg/kg, about 1.5 pg/kg, about 1.75 pg/kg, about 2.0 pg/kg, about 2.25 pg/kg, about 2.5 pg/kg, about 2.75 pg/kg, about 3 pg/kg, or any dose in between, followed by intravenous administration at a second step-up dose of about 5 pg/kg, about 7.5 pg/kg, about 10 pg/kg, about 12.5 pg/kg, about 15 pg/kg, or any dose in between, followed by intravenous administration at a step-up dose of about 40 pg/kg, about 50 pg/kg, about 60 pg/kg, about 70 pg/kg, about 80 pg/kg, or any dose in between, followed by weekly, biweekly, triweek
• the GPRC5DxCD3 bispecific antibody is administered subcutaneously at a step-up dose, followed by weekly, biweekly, triweekly or monthly administration at a higher dose.
• the GPRC5DxCD3 bispecific antibody can be administered subcutaneously at a step-up dose of about 1.5 pg/kg, about 5 pg/kg, about 10 pg/kg, about 20 pg/kg, about 40 pg/kg, about 45 pg/kg, about 60 pg/kg, or any dose in between, followed by weekly subcutaneously administration at a dose of about 5 pg/kg, about 10 pg/kg, about 15 pg/kg, about 20 pg/kg, about 25 pg/kg, about 30 pg/kg, about 40 pg/kg, about 45 pg/kg, about 50 pg/kg, about 55 pg/kg, about 60 pg/kg, about 80 pg/kg, 120 pg
• a GPRC5DxCD3 bispecific antibody is administered subcutaneously at a first step-up dose, followed by administration at a second higher step-up dose, followed by weekly, biweekly, triweekly or monthly administration at a third, higher dose.
• the GPRC5DxCD3 bispecific antibody can be administered subcutaneously at a step-up dose of about 1.5 pg/kg, about 5 pg/kg, about 10 pg/kg, about 15 pg/kg, or any dose in between, followed by subcutaneously administration at a higher step-up dose of about 30 pg/kg, about 40 pg/kg, about 45 pg/kg, about 60 pg/kg or any dose in between, followed by weekly subcutaneously administration at a dose of about 100 pg/kg, about 135 pg/kg, about 240 pg/kg, about 300 pg/kg, about 400 pg/kg, about 405 pg/kg, about 800 pg/kg, about 1000 pg/kg, about 1200 pg/kg, about 1600 pg/kg, about 2000 pg/kg, about 2400 pg/kg or any dose in between.
• a GPRC5DxCD3 bispecific antibody is administered subcutaneously at a first step-up dose, followed by administration at a second higher step-up dose, followed by administration at a third, higher step-up dose, followed by weekly, biweekly, triweekly or monthly administration at a fourth, higher dose.
• the GPRC5DxCD3 bispecific antibody can be administered subcutaneously at a first step-up dose of about 1.5 pg/kg, about 4pg/kg, about 6 pg/kg, about 8 pg/kg, about 10 pg/kg, about 12 pg/kg, about 14 pg/kg, about 16 pg/kg, about 18 pg/kg, about 20 pg/kg, or any dose in between, followed by subcutaneously administration at a second step-up dose of about 30 pg/kg, about 45 pg/kg, about 60 pg/kg, about 75 pg/kg, about 100 pg/kg, or any dose in between, followed by subcutaneously administration at a third step-up dose of about 150 pg/kg, about 200 pg/kg, about 250 pg/kg, about 300 pg/kg, about 350 pg/kg, about 400 pg/kg, or any dose in between, followed by weekly subcutaneous administration at a dose
• a GPRC5DxCD3 bispecific antibody is administered for a time sufficient to achieve complete response, stringent complete response, very good partial response, partial response, minimal response or stable disease status, and can be continued until disease progression or lack of patient benefit.
• the disease status can be determined by any suitable method known to those skilled in the art in view of the present disclosure, including, e.g., analysis of serum and urine monoclonal protein concentrations, M-protein levels, GPRC5D levels.
• a GPRC5DxCD3 bispecific antibody is administered for a time sufficient to achieve complete response that is characterized by negative minimal residual disease (MRD) status.
• Negative MRD status can be determined by any method suitable method known to those skilled in the art in view of the present disclosure.
• negative MRD status is determined using next generation sequencing (NGS).
• NGS next generation sequencing
• negative MRD status is determined using EuroFlow, a sensitive flow cytometric test.
• negative MRD status is determined at 10' 4 cells, 10' 5 cells, or 10' 6 cells.
• the administration of GPRC5DxCD3 can be continued after the negative MRD status is achieved as a maintenance therapy.
• the administration of GPRC5DxCD3 is discontinued after the negative MRD status is achieved.
• a GPRC5DxCD3 bispecific antibody can also be administered prophylactically in order to reduce the risk of developing cancer, such as smoldering multiple myeloma (SMM), delay the onset of the occurrence of an event in cancer progression, and/or reduce the risk of recurrence when the cancer is in remission.
• SMM smoldering multiple myeloma
• a method of the application further comprises administering to the subject one or more other anti-cancer therapies.
• the one or more other anti-cancer therapies can include, without limitation, autologous stem cell transplants (ASCT), radiation, surgery, chemotherapeutic agents, CAR-T therapies, cellular therapies, immunomodulatory agents, targeted cancer therapies, and any combination thereof.
• a method of the application further comprises administering to the subject a therapy that reduces or depletes Treg, such as low-dose cyclophosphamide.
• the one or more other anti-cancer therapies can also include, without limitation, selinexor, belantamab mafodotin-blmf, isatuximab, venetoclax, lenalidomide, thalidomide, pomalidomide, bortezomib, carfilzomib, elotozumab, ixazomib, melphalan, CC-92480, dexamethasone, vincristine, cyclophosphamide, hydroxydaunorubicin, prednisone, rituximab, imatinib, dasatinib, nilotinib, bosutinib, ponatinib, bafetinib, saracatinib, tozasertib, danusertib, cytarabine, daunorubicin, idarubicin, mitoxantrone, hydroxyurea,
• the terms and phrases “in combination,” “in combination with,” “co-delivery,” and “administered together with” in the context of the administration of two or more therapies or components to a subject refers to simultaneous administration, overlapping administration or subsequent administration of two or more therapies or components.
• “Simultaneous administration” or “simultaneously administered” refers to administration of the two or more therapies or components within the same treatment period.
• two components are administered “within the same treatment period,” they can be administered in separate compositions according to their own administration schedules, as long as the periods of administration for the two components end around the same day or within a short time period, such as within 1 day, 1 week, or 1 month.
• “Overlapping administration” refers to administration of the two or more therapies or components not within the same overall treatment period, but with at least one overlapping treatment period. “Subsequent administration” refers to administration of the two or more therapies or components during different treatment periods, one after the other.
• the use of the term “in combination with” does not restrict the order in which therapies or components are administered to a subject. For example, a first therapy or component can be administered prior to, concomitantly with or simultaneously with, or subsequent to the administration of a second therapy or component.
• BLRM model refers to the Bayesian logistic regression model as described in Neuenschwander et al. Stat Med. 2008. 27(13): 2420-39.
• dose escalation the probability of dose-limiting toxicities (DLTs) from a BLRM with the EWOC (Escalation with overdose control) principle guides the dose escalation.
• EWOC Exposure with overdose control
• the BLRM with the EWOC principle will also be implemented in Part 2 (dose expansion).
• the following two-parameter BLRM is central to the calculation of the probability of DLTs when a subject’s planned maximum dose during the first cycle is d.
• IgG4 anti-GPRC5D/anti-CD3 bispecific antibody talquetamab (described in U.S. Patent No. 10,562,968, the content of which is incorporated herein by reference in its entirety) was made by Janssen Pharmaceuticals. It was produced by cultivation of recombinant Chinese Hamster Ovary cells followed by isolation, chromatographic purification, and formulation.
• Talquetamab comprises a GPRC5D binding arm GC5B596 and a CD3 binding arm CD3B219, the amino acid sequences of which are shown in Table 3 and Table 4, respectively. Table 3. Sequences of GPRC5D binding arm of Talquetamab
• Example 1 Mechanisms of Resistance and Determinants of Response of Talquetamab in Multiple Myeloma
• GPRC5D cell surface expression is significantly higher on malignant plasma cells in different stages of the disease (newly diagnosed (ND), relapsed/refractory (RR), and daratumumab- refractory (DARA-R)) than on normal plasma cells from healthy donors (Figure 6A).
• GPRC5D expression is also higher on MM cells than on other immune cells ( Figure 6B). This selective expression renders it an attractive target for immunotherapy.
• talquetamab showed substantial activity in GPRC5D+ cell lines ( Figure 7).
• BM-MNCs bone marrow mononuclear cells
• Figures 10A-10C shows the impact of tumor and immune characteristics.
• the level of target expression was an important determinant of response, as evidenced by superior MM cell lysis in samples with higher than median GPRC5D expression (in darker dots), when compared to lower GPRC5D expression (in lighter dots).
• Inferior MM cell lysis was observed in samples with low T-cell counts or low effector:target (E:T) ratios, and in those with a high frequency of Tregs, PD-1+ T-cells, HLA-DR+ activated T-cells, and in older patients.
• E:T effector:target
• Tregs and CD4+CD25- effector T cells were purified from a buffy coat. Tregs impaired T-cell proliferation, confirming their suppressive function. Tregs were significantly less potent to kill MM cells when redirected by talquetamab, compared to CD4+CD25- T-cells ( Figure 11C). This was accompanied by reduced secretion of IFN-y, TNF-a, IL-2 and granzyme B. Patients with high Treg counts may benefit from Treg depletion strategies, such as low-dose cyclophosphamide.
• BMSCs BM stromal cells
• MM cell lines were co-incubated with PBMCs and patient-derived BMSCs.
• Direct cellcell contact hampered MM cell lysis, while indirect contact (transwell) did not affect talquetamab activity ( Figures 12A and 12B).
• the protection conferred by BMSCs against talquetamab-mediated lysis may be due to acquired resistance of MM cells (e.g., altered target expression following adhesive interactions) and/or T-cell suppression.
• GPRC5D is a promising target for immunotherapeutic strategies and talquetamab showed marked ex vivo anti-MM activity, irrespective of disease stage or cytogenetic risk.
• Tumor-related factors GPRC5D expression
• differences in the composition of the BM microenvironment including E:T ratio and % of Tregs
• E:T ratio e.g. induction therapy
• Treg depletion can improve response to bispecific antibodies in MM.
• Bispecific antibody talquetamab was generated by controlled fragment antigen binding arm exchange from two parental antibodies; GC5B596, an anti-GPRC5D antibody that originated from mouse immunization using the human GPRC5D DNA and GPRC5D overexpressing rat basophilic leukemia cells; and CD3B219, an anti-CD3s antibody that originated from a public domain antibody, SP34, which was further humanized and affinity matured.
• Talquetamab binds to human and cynomolgus CD3 and GPRC5D, and to rodent GPRC5D, but not to rodent CD3 (see e.g., U.S. Patent No. 10,562,968).
• Talquetamab binds specifically to endogenous GPRC5D-expressing multiple myeloma cell lines in a dose -dependent manner, as measured by flow cytometry for all GPRC5D-positive cell lines that were tested (H929, MM.1R, and OPM-2). In contrast, Talquetamab did not bind to GPRC5D-negative cell lines, NALM-6 and Daudi cells. Talquetamab-mediated T Cell Dependent Cytotoxicity of GPRC5D-positive Cell Lines in Vitro
• the T cell-dependent killing potential of talquetamab in multiple myeloma cells was determined in a flow cytometry -based cytotoxicity assay. Increasing concentrations of talquetamab were incubated with pan T cells from 6 healthy donors, 3 GPRC5D- positive and 2 GPRC5D-negative cell lines, at an effector: target (E:T) ratio of 5:1.
• E:T effector: target ratio of 5:1.
• Talquetamab (but not the negative control null molecules) induced potent T cell activation with average EC50 (EC20) values for H929, MM.1R, OPM-2 of 0.082 (0.035), 0.014 (0.006), and 0.288 (0.168) nM, respectively, when incubated with GPRC5D-positive multiple myeloma cells and healthy donor pan T cells. This was not the case in the 2 negative control cells (NALM-6 and Daudi). In vitro cytokine release was assessed in the supernatant from T cell-mediated killing assay (using T cells from 6 healthy donors) with H929 cells.
• the observed values for the average EC 50 were as follows: interferon (IFN)-y: 1.120 (0.615) pg/mL; tumor necrosis factor (TNF)-a: 1.545 (0.805) pg/mL; interleukin (IL)-lp: 0.720 (0.462) pg/mL; IL-2: 1.962 (1.380) pg/mL; IL-4: 1.867 (1.733) pg/mL; IL-6: 0.684 (0.441) pg/mL; IL-8: 0.440 (0.273) pg/mL; IL- 10: 1.082 (0.670) pg/mL.
• IFN interferon
• TNF tumor necrosis factor
• IL interleukin
• IL-2 0.720 (0.462) pg/mL
• IL-2 1.962 (1.380) pg/mL
• IL-4 1.867 (1.733) pg/mL
• Talquetamab did not cause significant activation of T cells in the absence of target GPRC5D-positive cells in in vitro or in whole blood assay. These findings demonstrate the specificity of talquetamab.
• the effect of talquetamab on cytotoxicity, T cell activation, and cytokine release was also tested in an in vitro assay using whole blood from healthy donors.
• Whole blood was incubated with GPRC5D-positive (H929) multiple myeloma cells at an E:T ratio of 5:1 with increasing concentrations of talquetamab for 48 hours.
• EC50 (EC 20) values for healthy donors were as follows: cytotoxicity 0.389 (0.131) nM, cytokine IL- 100.107 (0.032) nM, and T cell activation 0.236 (0.083) nM.
• T cell -mediated cytotoxicity assays were performed using H929 cells with increased concentrations of talquetamab up to 532 nM. Talquetamab showed a dose-dependent cytotoxicity and T cell activation up to the top concentration of 532 nM and no epitope saturation effect was observed.
• GPRC5D x CD3 bispecific antibody talquetamab was evaluated in 3 GPRC5D-positive human multiple myeloma models in peripheral blood mononuclear cell (PBMC) -humanized NOD scid gamma (NSG, NOD.Cg-Prkdcscid) mice.
• PBMC peripheral blood mononuclear cell
• NSG NOD scid gamma
• Two models were used: a prophylactic model in which treatment was initiated at the time of tumor cell implantation (H929), or an established model in which treatment was initiated after palpable tumors were formed (MM. IS and RPMI 8226).
• mice were engrafted with 10 million PBMCs one week prior to tumor inoculation with 5xl0 6 H929 cells subcutaneous. Treatment with talquetamab at 0.1, 1, or 10 pg per mouse (corresponding to 0.005, 0.05, or 0.5 mg/kg) was initiated immediately and repeated every 3 to 4 days thereafter for a total of 5 doses.
• Talquetamab elicited complete blockade of tumor formation at dose levels of either 10 or 1 pg/mouse, and 0.1 pg/mouse either blocked tumor formation or significantly suppressed growth as compared with phosphate - buffered saline (PBS)-treated control mice (97.6% mean tumor growth inhibition as compared with control mice, p ⁇ 0.01).
• PBS phosphate - buffered saline
• mice were inoculated with 1 x 10 7 cells subcutaneously. One week later 10 million PBMCs were engrafted. Two weeks after tumor cell implantation, treatment with either GPCR5D x CD3 bispecific antibody talquetamab (0.1, 1, 10, or 50 pg per mouse), CD3 x null, or GPRC5D x null (10 pg per mouse) was initiated and repeated every 3 to 4 days thereafter for a total of 7 doses. Antitumor efficacy was observed with 10 and 50 pg/animal dose levels of talquetamab bispecific antibody, with 10 out of the 10 complete responses (CR) (100% tumor regressions) in each group.
• CR complete responses
• the 1 pg per mouse dose significantly inhibited tumor growth by 65% as compared with PBS-treated control animals (p ⁇ 0.05), whereas the CD3 x null bispecific antibody nor the GPRC5D x null bispecific antibody failed to suppress tumor growth in the model.
• Talquetamab was administered IV once weekly for 4 weeks in a non-good laboratory practice (GLP) tolerability study in cynomolgus monkeys and was well tolerated up to 30 mg/kg. There were no talquetamab related clinical signs, significant pharmacodynamic effects (e.g., cytokine release) or adverse effects on safety parameters. Other notable changes were non-adverse and generally consistent with the expected mechanism of action of talquetamab and included transient and mild decreases in lymphocyte counts. It was determined that talquetamab had an approximately 100-fold lower in vivo pharmacological activity to GPRC5D in cynomolgus monkeys compared with humans. Based on the poor cross-reactivity, lack of adverse effects, and minimal pharmacodynamic effects observed in this study, further nonclinical safety studies with talquetamab in the cynomolgus monkey were not considered useful for human risk assessment.
• GLP non-good laboratory practice
• hazard identification studies in cynomolgus monkey were conducted with the surrogate molecule, talquetamab, which had cross-reactivity to cGPRC5D, and its functional activity in cynomolgus monkey cells was similar to the activity of talquetamab in human cells and was considered pharmacologically relevant in cynomolgus monkey.
• talquetamab was well tolerated and no effects were noted on safety pharmacology parameters (cardiovascular, respiratory, or central nervous system function).
• talquetamab No unanticipated cross-reactivity was observed.
• the ability of talquetamab to induce cytokine release in human donor blood was assessed using the soluble phase assay format assay.
• a solid phase assay format was also tested.
• talquetamab induced statistically significant, dose-dependent increases in IL-ip, IL-2, IL-6, IL-8, IL-10, IL-13, IFNy, and TNFa, relative to control.
• talquetamab induced statistically significant release in 9 of the 10 cytokines (IL-ip, IL-2, IL-4, IL-6, IL-8, IL- 10, IL- 13, IFNy, and TNFa).
• systemic talquetamab exposure increased with dose in an approximately dose-proportional manner following IV administration of talquetamab as a single dose of 0.5 and 5 mg/kg in an rHSA formulation or 0.5 mg/kg in formulation buffer in a pharmacokinetic study.
• Talquetamab exposure also increased with dose in an approximately dose-proportional manner following weekly doses of 0.5 to 30 mg/kg in an exploratory 4-week tolerability study.
• the serum half-life of talquetamab was estimated at 9 to 12 days in cynomolgus monkeys.
• Example 5 Phase 1 Study of Talquetamab Administered as Monotherapy for Relapsed or Refractory Multiple Myeloma
• a first- in-human (FIH), phase 1, open-label, multicenter study of talquetamab administered to adult subjects with relapsed or refractory multiple myeloma was carried out (NCT03399799).
• the study was conducted in 2 parts, separately for IV and SC administration: dose escalation (Part 1) and dose expansion (Part 2).
• the overall aim of the study was to evaluate the safety of talquetamab. Safety was monitored by a Study Evaluation Team (SET).
• a diagram of the dose escalation scheme is provided in Figure 1.
• ECG Eastern Cooperative Oncology Group
• WOCBP Women of childbearing potential
• P-hCG human chorionic gonadotropin
• ICF informed consent form
• Consent is to be obtained prior to the initiation of any study -related tests or procedures that are not part of standard of care for the subject’s disease.
• Prior Grade 3 or higher CRS related to any T cell redirection e.g., CD-3 redirection technology or CAR-T cell therapy
• any prior GPRC5D targeting therapy e.g., CD-3 redirection technology or CAR-T cell therapy
• Gene modified adoptive cell therapy e.g., chimeric antigen receptor modified T cells, natural killer [NK] cells.
• Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
• Central nervous system involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required.
• Plasma cell leukemia >2.0 x 10 9 /L plasma cells by standard differential
• Waldenstrom s macroglobulinemia
• POEMS syndrome polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M-protein], and skin changes
• AL amyloid light chain
• Hepatitis B infection as defined according to the American Society of Clinical Oncology guidelines. In the event the infection status is unclear, quantitative levels are necessary to determine the infection status. Active Hepatitis C infection as measured by positive HCV-RNA testing. Subjects with a history of Hepatitis C virus antibody positivity must undergo HCV-RNA testing.
• pharmacokinetic/immunogenicity sample would be collected any time a suspected infusion-related reaction (IRR) or cytokine release syndrome (CRS) event (in case of a CRS event, samples will be collected at onset, 24 hours, and 72 hours) was observed during the study.
• IRR infusion-related reaction
• CRS cytokine release syndrome
• pharmacokinetic and immunogenicity samples were collected at the End-of-Treatment visit following study drug discontinuation. The exact dates and times of blood sampling were recorded on the laboratory requisition forms. Collected samples were stored under specified controlled conditions for the temperatures indicated in the Laboratory Manual.
• Venous blood samples were collected for measurement of serum concentrations of talquetamab.
• the serum sample would be evenly divided into 2 aliquots (1 for pharmacokinetics; 1 for backup).
• 1 blood draw was collected and the serum was evenly divided into 3 aliquots (1 each for pharmacokinetics, antibodies to study drug, and a backup).
• Bone marrow aspirate might also be analyzed for pharmacokinetics, if feasible. Data were used for mechanistic pharmacokinetic/pharmacodynamic modeling. Samples collected for analyses of talquetamab serum concentration and antibody to talquetamab might be used to evaluate soluble B cell maturation antigen (sBCMA) or to evaluate safety or efficacy aspects that address concerns arising during or after the study period for further characterization of immunogenicity .
• sBCMA soluble B cell maturation antigen
• Pharmacokinetics Serum samples were analyzed to determine concentrations of talquetamab using a validated, specific, and sensitive assay method by or under the supervision of the sponsor.
• Immuno genicity The detection and characterization of anti-talquetamab antibodies were performed using a validated or appropriately qualified assay methods by or under the supervision of the sponsor. All samples collected for detection of antibodies to talquetamab would also be evaluated for talquetamab serum concentration to enable interpretation of the antibody data.
• Pharmacokinetic Parameters The detection and characterization of anti-talquetamab antibodies were performed using a validated or appropriately qualified assay methods by or under the supervision of the sponsor. All samples collected for detection of antibodies to talquetamab would also be evaluated for talquetamab serum concentration to enable interpretation of the antibody data.
• Pharmacokinetic parameters were estimated for individuals, and descriptive statistics were calculated for each dose level. Cmax and AUC with dose might also be explored. Pharmacokinetic parameters include, but were not limited to, AUCmf, AUC(o-t), AUC tau , C max , T1/2, time to reach the Cmax (Tma ), CL (for IV administration), CL/F (for SC administration), volume of distribution at steady-state ([Vss] for IV administration); and Vss/F (for SC administration) parameters were calculated if sufficient data were available for estimation.
• AUC area under the serum concentration versus time curve
• AUCinf area under the serum concentration versus time curve from time 0 to infinity with extrapolation of the terminal phase
• AUC(o-t) area under the concentration-time curve from time zero to time t
• AUCt au area under the serum concentration versus time curve during a dose interval time period (tau) at steady-state
• C ma x maximum observed serum concentration
• T1/2 half-life
• T max time to reach the C ma x (multiple doses)
• CL total systemic clearance of drug after intravenous administration
• Vss volume of distribution at steady-state).
• Antibodies to talquetamab were evaluated in serum samples collected from all subjects according to schedules. Additionally, serum samples were also collected at the final visit from subjects who were discontinued from treatment or withdrawal from the study. These samples were tested by the sponsor or sponsor’s designee. Serum samples were screened for antibodies binding to talquetamab and the titer of confirmed positive samples were reported. The ADA-positive (anti-drug antibodypositive) samples were tested for neutralizing antibodies to talquetamab. Immune response analysis might be conducted on pharmacokinetic samples collected at other timepoints, if deemed necessary. Receptor Occupancy (RO)
• Biomarker evaluations were completed in both Part 1 and Part 2.
• the biomarker assessments focused on several main objectives: 1) evaluate cytokine production in response to study drug administration; 2) evaluate the immune responses indicative of T cell redirection for potential contributions to study drug response; 3) determine the clinical benefit of study drug in subjects with cytogenetic modifications (dell7p, t(4; 14), t( 14; 16), or other high-risk molecular subtypes); and 4) determine the ability of study drug to reduce minimal residual disease (MRD) in subjects who had at least a complete response (CR). All biomarker assessments were performed at a central laboratory. If it became necessary, additional biomarker samples might be collected to help understand an unexplained event and specifically additional sample(s) for cytokines would be collected any time a suspected IRR or CRS event was observed or reported during the study.
• Biomarker analyses were dependent upon the availability of appropriate biomarker assays and might be deferred or not performed, if during or at the end of the study, it became clear that the analysis would not have sufficient scientific value for biomarker evaluation, or if there were not enough samples or responders to allow for adequate biomarker evaluation. In the event the study was terminated early or showed poor preliminary clinical antitumor activity, completion of biomarker assessments was based on justification and intended utility of the data. Additional Collections Based on emerging scientific evidence, the sponsor might request additional material from previously collected bone marrow samples during or after study completion for a retrospective analysis. In this case, such analyses would be specific to research related to the study drug(s) or diseases being investigated.
• Serum samples were collected before and at multiple time points after talquetamab administration at step-up or full treatment doses as scheduled. Cytokine were detected and measured using multi-plexed analyte panels (Luminex or MEsoScaleDiscovery technology). Analyses monitored included, but were not limited to TNF-a, IL-2, IL-6, INF-y, IL- 10, and IL-2Ra, which can inform on relative activation of immune cells.
• Whole blood samples and bone marrow aspirate samples might be analyzed to evaluate tumor and immune cell populations by flow cytometry and/or cytometry by time of flight (CyTOF) in order to determine if treatment with talquetamab results in increased antitumor activity by redirected T cell-mediated killing of GPRC5D-positive multiple myeloma cells and increased activation of cytotoxic T cells.
• CDT time of flight
• Whole blood T cell functionality assays might also be performed to study how this could affect drug response.
• whole blood samples collected pre- and post-talquetamab administration were analyzed using multi-color flow cytometry to assess immune populations, including, but not limited to, CD8+, CD4+ total and regulatory T cells, as well as naive and memory T cell subsets.
• activation/exhaustion markers including CD25, PD-1, TIM-3, LAG-3, HLA-DR and CD38 were also measured on CD8+ and CD4+ total and naive/memory T cell sub.
• DNA/RNA sequencing from tumor cells might be performed, for translocation/mutation/genomic analysis to assess whether specific molecular subgroups such as dell7p, t(4; 14), t( 14; 16) or other risk associated mutations/translocations were responsive to treatment and to identify potential predictive biomarkers of response and/or resistance.
• GPRC5D and PD-L1 expression on plasma cells at baseline may also be measured by flow cytometry on multiple myeloma cells in bone marrow samples to determine if antigen expression level or checkpoint ligand upregulation is a predictive biomarker of response.
• Baseline immunopheno typing including, but not limited to, frequency and activation/exhaustion of T cell subsets may also be performed on bone marrow aspirates to determine potential predictive biomarkers of response and/or resistance.
• Minimal residual disease negativity was being evaluated in the field as a potential surrogate for progression-free survival (PFS).
• Baseline bone marrow aspirates will be used to define the myeloma clones, and posttreatment samples would be used to evaluate MRD negativity in those subjects who experience a CR/stringent complete response (sCR).
• sCR CR/stringent complete response
• a fresh bone marrow aspirate was to be collected at screening, where clinically feasible. If bone marrow aspirate was not available at screening, non-decalcified diagnostic tissue, such as non-decalcified slides (bone marrow aspirate, touch preparation or clot selection) or formalin-fixed, paraffin- embedded block (clot section only, no bone marrow biopsy), must be supplied for MRD assessment instead.
• Minimal residual disease would be monitored in subjects using next generation sequencing on bone marrow aspirate DNA. If this methodology is unavailable, or determined to be scientifically inferior, then alternative methods for MRD assessment might be utilized.
• Disease evaluations were performed at the end of each treatment cycle and prior to the start of the next cycle. Disease evaluations scheduled for treatment days should be collected before study drug is administered. Disease evaluations would be performed by a central laboratory until disease progression. This study would use the 2016 IMWG- based response criteria. If it was determined that the study drug interferes with the immunofixation assay, CR would be defined as the disappearance of the original M- protein associated with multiple myeloma on immunofixation, and the determination of CR would not be affected by unrelated M-proteins secondary to the study drug. Subjects who relapse should not be taken off treatment and disease evaluations would continue until disease progression is confirmed.
• Serum quantitative immunoglobulins IgG, IgA, IgM, IgE, and IgD at screening.
• Samples for serum quantitative immunoglobulins (IgG, IgA, IgM, IgE, and IgD) were also collected at screening and every 4 weeks thereafter to be analyzed locally. Blood and 24-hour urine samples were collected until the development of confirmed disease progression. Disease progression based on one of the laboratory tests alone were confirmed by at least 1 repeat investigation performed 1 to 3 weeks later. Disease evaluations would continue beyond relapse from CR until disease progression was confirmed.
• Serum and urine immunofixation and serum free light chain (FLC) assay would be performed at screening and thereafter when a CR was suspected (when serum or 24-hour urine M-protein electrophoresis [by serum protein electrophoresis or urine M- protein quantitation by electrophoresis (UPEP)] were 0 or non-quantifiable). Both serum and urine immunofixation test would be performed routinely for subjects with light chain multiple myeloma.
• bone marrow aspirate or biopsy were performed for clinical assessments and biomarker evaluations.
• Clinical staging morphology, cytogenetics, and immunohistochemistry or immunofluorescence or flow cytometry
• a bone marrow aspirate sample was required to confirm CR and sCR; the sample must be collected and the results obtained prior to the next scheduled dose of study drug.
• a bone marrow aspirate sample was also collected at Cycle 3 Day 1 and at the time of disease progression, if clinically indicated.
• MRD might be evaluated at the time of suspected CR/sCR, and for subjects with confirmed CR/sCR, an additional bone marrow aspirate was obtained 12 months post C1D1 ( ⁇ 1 month) and yearly ( ⁇ 1 month) thereafter.
• a complete skeletal survey (including skull, entire vertebral column, pelvis, chest, humeri, femora, and any other bones for which the investigator suspects involvement by disease) was to be performed during the screening phase and evaluated locally by either roentgenography or low dose CT scans without the use of IV contrast.
• X-rays, or CT scans would be performed locally, whenever clinically indicated based on symptoms, to document response or progression.
• Magnetic resonance imaging was an acceptable method for evaluation of bone disease and might be included at the discretion of the investigator; however, it would not replace the skeletal survey. If a radionuclide bone scan was used at screening in addition to the complete skeletal survey, then both methods must be used to document disease status. These tests must be performed at the same time. Note: a radionuclide bone scan would not replace a complete skeletal survey.
• Subjects might present with disease progression manifested by symptoms of pain due to bone changes. Therefore, disease progression might be documented, in these cases, by skeletal survey or other radiographs, depending on the symptoms that the subject experiences. If the diagnosis of disease progression was obvious by radiographic investigations, then no confirmatory X-rays were necessary. In instances in which changes were subtler, a repeat X ray might be needed in 1 to 3 weeks.
• Extramedullary Plasmacytomas Sites of known extramedullary plasmacytomas must be documented during the screening phase. Clinical examination or MRI might be used to document extramedullary sites of disease. CT scan evaluations were an acceptable alternative if there is no contraindication to the use of IV contrast. Positron emission tomography (PET)-CT was allowed if CT alone was not available. Ultrasound tests were not acceptable to document the size of extramedullary plasmacytomas.
• PET Positron emission tomography
• Extramedullary plasmacytomas were assessed for all subjects with a history of plasmacytomas or if clinically indicated at screening, by clinical examination or radiologic imaging. Assessment of measurable sites of extramedullary disease would be performed, measured, and evaluated locally every 4 weeks (for physical examination) for subjects with a history of plasmacytomas or as clinically indicated during treatment for other subjects until development of confirmed CR or confirmed disease progression. If assessment could only be performed radiologic ally, then evaluation of extramedullary plasmacytomas might be done every 12 weeks (+ 2 weeks). For every subject, the methodology used for evaluation of each disease site was consistent across all visits. Irradiated or excised lesions would be considered not measurable and would be monitored only for disease progression.
• CBR clinical benefit rate
• DOR duration of response
• TTR time to response
• PFS progression-free survival
• MRD minimal residual disease
• IV administration A whole blood in vitro assay system from healthy human donors was used to estimate the minimum anticipated biologic effect level (MABEL) - based starting dose. A dose of 0.5 pg/kg IV administered over approximately 4-hours once every 2 weeks was selected based on the lowest mean EC20 from the most relevant assay among T cell activation, cytotoxicity, and cytokine release. Subsequent bi-weekly IV dose levels were selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
• MABEL minimum anticipated biologic effect level
• SC administration talquetamab was administered subcutaneously (SC) on a weekly dosing schedule. Dose escalation for the SC dosing cohort began with a 1.5 pg/kg priming dose administered SC on Day -7, followed by a full dose of 5 pg/kg administered SC on Days 1, 8, and 15 of a 21-day cycle. Subsequent SC dose levels were selected based on a statistical model using all available data to identify safe and tolerable putative RP2D(s), defined as the dose(s) of talquetamab for characterization in Part 2.
• IMWG IMWG
• the primary objectives of the dose escalation phase are to characterize the safety of talquetamab and to identify a recommended phase 2 dose (RP2D). Escalating doses of IV or SC talquetamab (0.5-800 pg/kg) with and without step-up dosing were assessed. Key secondary objectives include characterizing the pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of talquetamab. Adverse events (AEs) were graded using the Common Terminology Criteria for AE, v4.03, and cytokine release syndrome (CRS) was graded according to Lee et al (Blood 2014; 124: 188).
• PK pharmacokinetics
• CRS cytokine release syndrome
• PK results from IV dosing indicated that the half-life of talquetamab supports weekly dosing. SC results showed lower Cmax with comparable trough levels than that of IV dosing (at a similar dose) which makes it a favorable administration option.
• CR complete response
• IV intravenous
• MR minimal response
• QW weekly
• Q2W every 2 weeks
• ORR overall response rate
• PD progressive disease
• PR partial response
• SC subcutaneous
• sCR stringent complete response
• SD stable disease
• VGPR very good partial response.
• PK profile following first treatment dose shows that the exposure was dose-proportional following first dose in 5-405 pg/kg SC cohorts. 405 pg/kg SC cohorts had lower peak/trough ratio than 60 pg/kg IV cohorts and maintained exposure over the maximum EC90. Thus, there is opportunity for less frequent SC dosing.
• ADA anti-drug antibody
• ADA did not appear to impact safety, PK, or efficacy.
• cytokines IL- 10, IL-6, IL2Ra
• PD-1 + T cells were induced in the periphery, indicative of T cell activation
• consistent T cell activation was observed at RP2D of 405 pg/kg SC.
• the data analysis also demonstrates that, 1) at most active doses of 20-180 pg/kg IV and 235-800 pg/kg SC, the ORR was 66% (33/50), >VGPR was 42%, and the responses deepened over time; 2) at the RP2D of 405 pg/kg SC, the ORR was 69% (9/13), the median time to first confirmed response was 1 month (1-2), 6/9 (67%) of the responders were triple-class refractory, and 2/9 (22%) of the responders were penta-drug refractory.
• duration of response (DPR) data (Figure 5A, the data for IV cohorts were more mature at time of analysis) shows that the responses were durable and deepened over time and the median time to first confirmed response across all doses was 1 month (0.2-3).
• DPR duration of response
• Subcutaneous (SC) administration of escalating doses of talquetamab (5-800 pg/kg) with and without step-up dosing were assessed in additional cohorts and longer follow-up time using the same study design described above ( Figure IB). Patients must have had measurable disease and have progressed on or could not tolerate all available established therapies. Prior BCMA-targeted therapy was allowed. Premedications (i.e., glucocorticoid, antihistamine, and antipyretic) were limited to step-up doses and the first full dose; however, there was no steroid requirement after the first full dose.
• Premedications i.e., glucocorticoid, antihistamine, and antipyretic
• Table 9 Summary of Patient Demographics and Disease Characteristics (SC, QW)
• BCMA B-cell maturation antigen
• CAR-T chimeric antigen receptor T-cell
• IMiD immunomodulatory drug
• ISS In ternational Staging System
• mAb monoclonal antibody
• PI proteasome inhibitor
• QW weekly
• RP2D recommended phase 2 dose
• SC subcutaneous a Step-up doses of 10 and 60 pg/kg.
• BCMA CAR-T therapy or BCMA non- CAR-T therapy f >l PI, >1 IMiD, and 1 anti-CD38 mAh.
• talquetamab has a tolerable safety profile at the RP2D of 405 pg/kg. No dose-limiting toxicities and deaths due to AEs were observed at the RP2D. Cytopenias were mostly confined to the step-dosing and to the first and second treatment cycles. Neutropenias generally resolved within a week and were limited to the first and second treatment cycles. Infections were observed in 37% of the patients evaluated (9% for grade 3 or 4) and in 32% of patients at the RP2D (3% for grade 3 or 4). Neurotoxicities were observed in 4 patients with SC dosing (all grade 1 or 2) and in 2 patients (7%) at the RP2D.
• Injection-site reactions occurred in 17% of patients, including at the RP2D), but were mild and manageable (all grade 1 or 2).
• Skin-related AEs includes skin exfoliation, pruritis, rash, and nail disorders
• Nail disorders includes onychomadesis and nail dystrophy occurred in 21% of patients (27% of patients at the RP2D).
• neutropenia 57% at any grade, 49% at grade 3 or 4
• anemia 45% at any grade, 28% at grade 3 or 4
• leukopenia 26% at any grade, 20% at grade 3 or 4
• thrombocytopenia 28% at any grade, 18% at grade 3 or 4
• CRS CRS
• dysgeusia 46% at any grade, not applicable at grade 3 or 4
• fatigue 32% at any grade, 0% at grade 3 or 4).
• AEs adverse events
• CRS cytokine release syndrome
• DLT dose -limiting toxicity
• NA not applicable
• RP2D recommended phase 2 dose
• SC subcutaneous a Step-up doses of 10 and 60 pg/kg.
• b includes skin exfoliation, pruritis, rash, and nail disorders
• C includes nail disorders, onychomadesis and nail dystrophy.
• CRS was generally limited to grade 1 or 2 in all subjects (with the exception of one patient with grade 3 CRS) and the severity appears to be mitigated by implementation of step-up dosing and SC administration (Figure 14).
• Median time to CRS onset was 2 days (range 1-22 days) and median duration of CRS was 2 days (range 1-7 days).
• supportive measures to treat their CRS e.g., tocilizumab, steroids, low-flow oxygen by nasal cannula, and vasopressor.
• a summary of the data pertaining to patients that experienced CRS is shown in Table 11.
• CRS cytokine release syndrome
• QW weekly
• RP2D recommended phase 2 dose
• SC subcutaneous a Step-up doses of 10 and 60 pg/kg.
• b Relative to the most recent dose.
• the RP2D of 405 pg/kg SC QW was administered to 30 patients with a median follow-up of 6.3 months (range 1.4-12 months) for the responders.
• the data analysis ( Figure 4) demonstrates that for the escalating doses of talquetamab (5-800 pg/kg) in 75 patients, note that not all 82 patients were available for evaluation) the ORR was 53.3% (40/75) and >VGPR was 44%; 2) at the RP2D of 405 pg/kg SC, the ORR was 70% (21/30), >_VGPR was 60%, the median time to first confirmed response was 1 month (range 0.2-3.8 months), 15/23 (65.2%) of the responders were triple-class refractory, and 5/6 (83.3%) of the responders were penta-drug refractory.
• the ORR was assessed in evaluable patients who had >1 dose of talquetamab and >1 post-baseline disease evaluation per the 2011 International Myeloma Working Group response criteria. Out of 6 evaluable patients across the IV and SC cohorts, 4 had negative MRD CR/sCR at 10' 6 , including 1 subject in the RP2D cohort. Negative MRD was sustained 7 months postcomplete response in 1 evaluable patient.
• duration of response data show that the responses were durable and deepened over time in 40 patients treated with SC doses of talquetamab ranging from 45 to 800 pg/kg.
• SC QW Figure 5C
• median duration of response was not reached and after median follow-up of 6.3 months (range 1.4-12.2+ months), 17/21 responders (81%) were alive and remained on talquetamab treatment.
• the data for IV cohorts (Figure 5A) was more mature and even at subtherapeutic doses, responses were ongoing at 22+ months in patients with longer follow-up.
• PK pharmacokinetics
• 800 pg/kg of talquetamab was also well tolerated and highly effective. Patients were treated weekly or biweekly with 800 pg/kg of talquetamab.
• Talquetamab had a manageable safety profile across all doses assessed: most CRS events (67%) were grade 1-2 and generally confined to first step-up and full doses; step-up dosing mitigated high-grade CRS; there was a low incidence of neurotoxic events which were predominantly grade 1-2.
• Talquetamab specific skin-related AEs includes skin exfoliation, pruritis, rash, and nail disorders occurred in 67% of patients.
• Part 1 and 2 Additional Patients and Longer Follow-up for The SC Administration (Cut-off Date for Analyses July 19, 2021)
• the median age for the 30 subjects receiving talquetamab SC at the RP2D of 405 pg/kg SC weekly was 61.5 years (range: 46 to 80 years), with 7 (23.3%) subjects >70 years of age.
• the median number of prior therapeutic regimens was 6 (range: 2 to 14).
• All 30 subjects (100%) were prior triple-exposed (prior therapy included PI, IMiD, and anti-CD38 monoclonal antibody) and 80.0% were prior penta-exposed (prior therapy included 2 or more Pls, 2 or more IMiDs, and an anti-CD38 monoclonal antibody).
• all 30 subjects were refractory to anti-CD38 monoclonal antibody therapy, 76.7% were triple -refractory, and 20.0% were penta-refractory.
• the median age for the 23 subjects receiving talquetamab SC at the RP2D of 800 pg/kg SC biweekly was 60.0 years (range: 47 to 84 years), with 7 (30.4%) subjects >70 years of age.
• the median number of prior therapeutic regimens was 5 (range: 1 to 17).
• Twenty-two subjects (95.7%) were prior triple-exposed (prior therapy included PI, IMiD, and anti-CD38 monoclonal antibody) and 69.6% were prior penta-exposed (prior therapy included 2 or more Pls, 2 or more IMiDs, and an anti-CD38 monoclonal antibody).
• 78.3% were refractory to anti-CD38 monoclonal antibody therapy
• 65.2% were triple -refractory
• 21.7% were penta-refractory.
• the median age for the 97 subjects receiving talquetamab SC at any dosage was 64.0 years (range: 39 to 84 years), with 28 (28.9%) subjects >70 years of age.
• the median number of prior therapeutic regimens was 6 (range: 1 to 17).
• Ninety-six subjects (99.0%) were prior triple-exposed (prior therapy included PI, IMiD, and anti-CD38 monoclonal antibody) and 78.4% were prior penta-exposed (prior therapy included 2 or more Pls, 2 or more IMiDs, and an anti-CD38 monoclonal antibody).
• 90.7% of subjects were refractory to anti-CD38 monoclonal antibody therapy, 71.1% were triple-refractory, and 22.7% were penta-refractory.
• talquetamab IV Another 102 subjects have been treated with talquetamab IV doses in this study.
• the efficacy and safety profiles of talquetamab IV are comparable to those of talquetamab SC.
• Subjects have received at least one study treatment and have at least one post-baseline response evaluation by investigator.
• Percentages are calculated with the number of subjects in each group as denominator.
• cytokine release syndrome CRS
• neutropenia 66.7%
• anemia dysgeusia
• lymphopenia 66.7%
• thrombocytopenia dysphagia
• skin exfoliation 36.7% each
• fatigue nail disorder (30.0% each)
• dry mouth hypophosphatemia, pruritus (26.7% each)
• headache diarrhea, nausea, rash, weight decreased (23.3% each)
• pyrexia dry skin, alanine aminotransferase increased, gamma-glutamyltransferase increased, oropharyngeal pain (20.0% each).
• TEAEs for subjects treated with talquetamab at the RP2D of 800 pg/kg SC biweekly (>20% of subjects) were CRS (78.3%); neutropenia, dry mouth (43.5% each); dysgeusia, fatigue, skin exfoliation, aspartate aminotransferase increased (30.4% each); anemia, dry skin, alanine aminotransferase increased (26.1% each); and lymphopenia, thrombocytopenia, decreased appetite, hypokalaemia (21.7% each).
• TEAEs The most frequently reported TEAEs (>20% of subjects) were CRS (70.1%); neutropenia (54.6%); anemia (46.4%); dysgeusia (45.4%); thrombocytopenia, skin exfoliation (30.9% each); lymphopenia, leukopenia, fatigue (28.9% each); dry mouth (25.8%); pyrexia (23.7%); dysphagia, alanine aminotransferase increased (22.7% each); nausea, nail disorder (21.6% each); diarrhea, weight decreased (20.6% each).
• TEAE treatment-emergent adverse event
• CRS cytokine release syndrome
• CRS events are linked for the same subject after the same infusion. If one CRS event is followed by another with an onset date the same as or 1 day after the end date of the previous CRS and any features of the CRS (i.e.: toxicity grades/seriousness/action taken) are different between the CRS events, these CRS events are linked together and considered as one event.
• e Neurotoxicity is defined as a potential neurotoxicity event that was considered related by investigator. Percentages are calculated with the number of subjects in each group as denominator.
• DLTs were evaluated in Part 1 (dose escalation) only.
• Part 1 dose escalation
• no subject who received talquetamab at the RP2D of 405 pg/kg SC weekly experienced a DLT
• l subject who received talquetamab at the RP2D of 800 ug/kg SC biweekly experienced a DLT (Table 13).
• No subjects in Part 2 experienced TEAEs meeting DLT criteria.
• Three DLTs have been reported in subjects receiving any dose of SC talquetamab (Table 13).
• One subject reported a SAE of Grade 3 maculopapular rash (deemed very likely related to talquetamab) after receiving two 135 pg/kg weekly treatment doses of talquetamab SC.
• the SAE improved to Grade 1 as of the data cutoff.
• One subject experienced a Grade 3 maculopapular rash after receiving a single 800 pg/kg treatment dose (weekly schedule) of talquetamab SC that was considered possibly related.
• One subject experienced a Grade 3 rash after receiving a single 800 ug/kg treatment dose (biweekly schedule) that was considered very likely related. Both events resolved and subjects continued on treatment and remain on treatment as of the data cutoff.
• Serious TEAEs were reported for 37 subjects (38.1%) receiving talquetamab SC (Table 13).
• Serious adverse events reported by more than 1 subject were CRS (6 subjects, 6.2%), pyrexia (5 subjects, 5.2%), hypercalcemia, febrile neutropenia, bone pain (3 subjects, 3.1%), influenza, urinary tract infection, somnolence (2 subjects, 2.1%).
• CRS CRS
• pyrexia 7.5%
• CRS Cytokine Release Syndrome
• talquetamab The mechanism of action of talquetamab is based on the binding and activation of T cells and the release of cytokines in the tumor environment, thus CRS is expected in patients receiving talquetamab and CRS is an important identified risk for talquetamab with mitigation strategies in place in all ongoing and planned clinical studies.
• CRS CRS is expected in patients receiving talquetamab and CRS is an important identified risk for talquetamab with mitigation strategies in place in all ongoing and planned clinical studies.
• subjects receive step-up doses of talquetamab, and premedications (glucocorticoid, antihistamine, and antipyretic) prior to each step-up dose and the first treatment dose of talquetamab per protocol.
• CRS CRS was reported in 23 subjects (76.7%) receiving the RP2D of 405 pg/kg SC Weekly, mostly Grade 1 (60.0%) or Grade 2 (1033%) (Table 13).
• CRS was only seen during early doses in Cycle 1, and the median duration of CRS was 2 days (range: 1 to 3 days).
• CRS was reported in 18 subjects (78.3%) receiving the RP2D of 800 pg/kg SC biweekly, all either Grade 1 (52.2%) or Grade 2 (26.1%) (Table 13). CRS was only seen during early doses in Cycle 1, and the median duration of CRS was 2 days (range: 1 to 5 days). Seventeen subjects (73.9%) received supportive measures as treatment for CRS (15 [65.2%] received tocilizumab, 1 subject [4.3%] each received corticosteroids, and supplemental oxygen).
• CRS was reported in 70.1% of subjects receiving talquetamab SC, mostly Grade 1 (50.5%) or Grade 2 (18.6%) (Table 13).
• Grade 1 50.5%) or Grade 2 (18.6%) (Table 13).
• One subject (1.0%) exhibited a Grade 3 CRS event.
• the incidence of CRS and associated symptoms appeared to be dose dependent.
• CRS was only seen during early doses in Cycle 1, and the median duration of CRS was 2 days (range: 1 to 5 days).
• Sixty-five subjects (67.0%) received supportive measures as treatment for CRS 50 [51.5%] received tocilizumab, 4 subjects [4.1%] received steroids, 2 subjects [2.1%] received vasopressors, and 8 subjects [8.2%] received supplemental oxygen).
• talquetamab Based on the mode of action of talquetamab, neurotoxicity is identified as an important potential risk.
• members of the ASTCT developed a severity grading system for CRS and ICANS events induced by CAR-T cells and may be applied to other biologies. It was published in April of 2019. This study began in January 2018; consequently, TEAEs in Part 1 and Part 2 of this study were not coded using the ASTCT guidelines.
• potential neurotoxicity events (regardless of investigator-assessed relatedness) were identified by the applicant’s medical team via review of TEAEs reported in the system organ classes of Nervous System Disorders and Psychiatric Disorders against a predetermined list.
• PK data are available from 69 subjects treated with SC talquetamab at doses ranging from 5 to 800 pg/kg weekly and 800 pg/kg biweekly from MonumenTAL-1. PK data are also available from 100 subjects treated with IV talquetamab at doses ranging from 0.5 to 3.38 pg/kg biweekly and 1.5 to 180 pg/kg weekly. Based on the safety, efficacy and PK, 405 pg/kg weekly SC administration was identified as the putative RP2D and being evaluated in the Part 2 and Part 3 (400 pg/kg for operational convenience) of MonumenTAL-1.
• the PK of talquetamab was further evaluated after talquetamab was subcutaneously administered weekly or biweekly. Following weekly SC administration, the concentration-time profiles demonstrated a less fluctuated and more sustained pattern. The preliminary results suggested the individual T max occurred on Day 2 to Day 8. At the similar dose level of talquetamab, Cmax was approximately 5.6-fold lower than that of IV treatment; talquetamab trough levels were comparable between IV and SC administration. The sponsor acknowledges that 400 pg/kg SC weekly will result in higher mean Ctrough, lower mean Cmax and similar mean C aV g at steady state compared to those at 800 pg/kg SC biweekly.
• This assay assessed the ability of talquetamab to induce killing using mononuclear cells from the bone marrow samples of patients with multiple myeloma in co-culture with T cells from healthy donors.
• the mean accumulation ratio (based on AUC tau ) following SC weekly dosing ranged from 1.7 to 5.1.
• preliminary population PK analysis and non-compartmental analysis showed that the mean bioavailability following SC weekly administration was 48%.
• cytokines such as IL- 10 (median maximum fold change 8.582; range: [1.42-73.82]), IL-2Ra (3.866; 1.47-27.84), and IL-6 (87.800; 1.45-1841.25).
• T cell activation markers such as CD25 (median maximum fold change 1.87 [range: 0.72 to 9.76]), PD-1 (1.94; 1.09-6.51), HLA-DR (1.324; 0.76-5.64), CD38 (2.952; 0.6-11.30), LAG-3 (3.221; 1.16-11.36), TIM-3 (3.442; 1.06-15.09) and T cell redistribution as indicated by changes in total T cell absolute counts (0.623; 0.2-4.18) were also observed in the 405 pg/kg cohort.
• CD25 median maximum fold change 1.87 [range: 0.72 to 9.76]
• PD-1 (1.94; 1.09-6.51
• HLA-DR 1.324; 0.76-5.64
• CD38 2.952; 0.6-11.30
• LAG-3 3.221; 1.16-11.36
• TIM-3 3.442; 1.06-15.09
• T cell redistribution as indicated by changes in total T cell absolute counts (0.623; 0.2-4.18)
• the RP2D was originally identified as a weekly SC dose of 405 pg/kg talquetamab with step-up doses of 10 and 60 pg/kg. Alternative dosing schedules that require less frequent administration continue to be investigated.
• a biweekly RP2D was also identified as a SC dose of 800 pg/kg talquetamab with step-up doses of 10, 60, and 300 pg/kg.
• Table 15 Summary of the simulated exposure metrics mean Cmax, Cmin, and AUC across different dosing regiments of talquetamab at cycle 2.
• SC administration Upon identification of the putative RP2D for SC administration, subjects were treated with 405 pg/kg as the SC QW RP2D in dose expansion (with step-up doses of 10 and 60 pg/kg) to further demonstrate safety and to characterize preliminary antitumor activity. Another subset of subjects were treated with 800 pg/kg as the SC biweekly RP2D dose in dose expansion (with step-up doses of 10, 60, and 300 pg/kg).
• Part 2 up to 40 subjects can be enrolled and treated with IV or SC talquetamab at an RP2D of 405 pg/kg or 800 pg/kg. Additionally, the same dosing schedules recommended in Part 1 may be used to further characterize preliminary antitumor activity and safety in additional subjects at the RP2D doses of interest. The same supportive care measures used in Part 1 of the study will be applied to the subjected treated in Part 2.
• the SET (Study Evaluation Team) may stop further enrollment into the dose expansion cohorts pending the outcome of any SET reviews, or if treatment- emergent toxicity is determined to result in an unfavorable change in subject risk or benefit.
• DLT dose-limiting toxicity
• Cohorts A, B, and C are representative of the subset of relapsed/refractory multiple myeloma patients who have limited treatment options. These cohorts are defined as follows:
• Cohort A 400 pg/kg weekly SC will enroll subjects with multiple myeloma who have previously received >3 prior lines of therapy that included at least one proteasome inhibitor (PI), one immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody, and have not been exposed to T cell redirection therapies such as CAR-T or bispecific antibodies.
• PI proteasome inhibitor
• IMD immunomodulatory imide drug
• anti-CD38 monoclonal antibody an anti-CD38 monoclonal antibody
• Cohort B 400 pg/kg weekly SC will enroll subjects with multiple myeloma who have previously received >3 prior lines of therapy that included at least one PI, one IMiD, and an anti-CD38 monoclonal antibody, and have been exposed to T cell redirection therapies such as CAR-T or bispecific antibodies.
• Cohort C (800 pg/kg bi-weekly SC) will enroll subjects with multiple myeloma who have previously received >3 prior lines of therapy that included at least one PI, one IMiD, and an anti-CD38 monoclonal antibody, and have not been exposed to T cell redirection therapies such as CAR-T or bispecific antibodies.
• Cohorts A and B will be enrolled after approximately 20 subjects have been treated with SC talquetamab at the RP2D of 400 pg/kg or 800 pg/kg for at least one cycle. The sponsor may also determine that additional subjects are required to further evaluate safety and dose prior to proceeding to Part 3. Enrollment for Cohort C will begin after 20 subjects have been treated with SC talquetamab at an RP2D of 800 pg/kg bi-weekly for at least 1 cycle. In contrast to Part 2, the selected RP2Ds for Part 3 are 400 pg/kg weekly and 800 pg/kg biweekly SC talquetamab until progressive disease. The putative RP2Ds in Part 2 are 405 pg/kg weekly and 800 pg/kg biweekly SC talquetamab until progressive disease.
• the priming dose schedule in Part 3 will consist of 2 doses (10 and 60 pg/kg), each separated by 2 to 4 days and will be completed 2 to 4 days prior to the first treatment dose (i.e., if there are no delays in treatment, the first priming dose (10 pg/kg) is to be administered 5 to 8 days before the first treatment dose and the second priming dose (60 pg/kg 2 to 4 days before the first treatment dose).
• the biomarkers of the patients in Part 3 also will be evaluated.
• An adverse event of special interest for Part 3 is a neurotoxicity grade > 2 (i.e., ICANS (immune effector cell-associated neurotoxicity syndrome), symptoms of ICANS, and non-ICANS neurotoxicity).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Luminescent Compositions (AREA)
• Magnetic Resonance Imaging Apparatus (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Compression Of Band Width Or Redundancy In Fax (AREA)

Priority Applications (9)

Applications Claiming Priority (6)

Publications (1)

Family

ID=77924410

Family Applications (1)

Country Status (11)

Cited By (5)

Families Citing this family (2)

Citations (8)

Family Cites Families (1)

• 2021
  • 2021-09-16 EP EP21778070.9A patent/EP4213945A1/en active Pending
  • 2021-09-16 AU AU2021346129A patent/AU2021346129A1/en active Pending
  • 2021-09-16 IL IL301361A patent/IL301361A/en unknown
  • 2021-09-16 KR KR1020237012190A patent/KR20230069959A/ko active Pending
  • 2021-09-16 WO PCT/EP2021/075523 patent/WO2022058445A1/en not_active Ceased
  • 2021-09-16 CN CN202180063247.6A patent/CN116322769A/zh active Pending
  • 2021-09-16 CA CA3194796A patent/CA3194796A1/en active Pending
  • 2021-09-16 MX MX2023003086A patent/MX2023003086A/es unknown
  • 2021-09-16 BR BR112023004830A patent/BR112023004830A2/pt unknown
  • 2021-09-16 JP JP2023517243A patent/JP2023542124A/ja active Pending
  • 2021-09-16 US US17/477,435 patent/US20220177584A1/en active Pending

Patent Citations (9)

Non-Patent Citations (30)

Also Published As

Similar Documents

Legal Events